Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Effects of sildenafil citrate and etanercept treatment on TNF-? levels in peripheral blood of women with recurrent miscarriage.
Abortion, Habitual
Effects of Sildenafil Citrate and Heparin Treatments on Placental Cell Morphology in a Murine Model of Pregnancy Loss.
Acidosis
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Acquired Immunodeficiency Syndrome
A nationwide population study of trazodone use in urology patients.
Acquired Immunodeficiency Syndrome
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Acquired Immunodeficiency Syndrome
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Acquired Immunodeficiency Syndrome
Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Acquired Immunodeficiency Syndrome
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Acquired Immunodeficiency Syndrome
Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes.
Acute Coronary Syndrome
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference.
Acute Coronary Syndrome
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Acute Kidney Injury
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.
Acute Kidney Injury
Phosphodiesterase-5 inhibition prevents postcardiopulmonary bypass acute kidney injury in swine.
Acute Lung Injury
Effects of phosphodiesterase 5 inhibitor sildenafil on the respiratory parameters, inflammation and apoptosis in a saline lavage-induced model of acute lung injury.
Acute Lung Injury
Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
Acute Lung Injury
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Adenocarcinoma
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Adenoma
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Adenomatous Polyposis Coli
Exisulind Cell Pathways.
Albinism
FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis.
Albuminuria
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Alopecia
Risk of erectile dysfunction associated with use of 5-? reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Alopecia
Treatment review for male pattern hair-loss.
Altitude Sickness
Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications.
Altitude Sickness
Re: ''Meta-Analysis of Clinical Efficacy of Sildenafil, a Phosphodiesterase Type-5 Inhibitor on High Altitude Hypoxia and Its Complications" by Xu et al.
Altitude Sickness
Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).
Alzheimer Disease
Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Alzheimer Disease
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Alzheimer Disease
Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer's disease.
Alzheimer Disease
Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Alzheimer Disease
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Alzheimer Disease
Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Alzheimer Disease
Discovery of in-vivo chemical probes for treating Alzheimer´s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitors.
Alzheimer Disease
Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice.
Alzheimer Disease
Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
Alzheimer Disease
Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Alzheimer Disease
Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5).
Alzheimer Disease
Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.
Alzheimer Disease
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Alzheimer Disease
Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-? peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease.
Alzheimer Disease
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Alzheimer Disease
Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review.
Alzheimer Disease
Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Alzheimer Disease
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Amnesia
The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.
Amnesia, Transient Global
Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Anemia, Sickle Cell
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Anemia, Sickle Cell
High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Anemia, Sickle Cell
Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.
Anemia, Sickle Cell
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism.
Anemia, Sickle Cell
Potential utility of full-spectrum antioxidant therapy, citrulline, and dietary nitrate in the management of sickle cell disease.
Anemia, Sickle Cell
Recurrent Priapism in a Military Veteran Receiving Treatment for PTSD.
Anemia, Sickle Cell
Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
Aneurysm, Dissecting
Type B aortic dissection after the use of tadalafil.
Angina Pectoris
Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells.
Angina Pectoris
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Angina Pectoris
Sexual function in patients with chronic angina pectoris.
Angina Pectoris
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
Antiphospholipid Syndrome
Treatment Algorithms in Systemic Lupus Erythematosus.
Aortic Valve Stenosis
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.
Arrhythmias, Cardiac
Effects of phosphodiestrase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression.
Arteriovenous Malformations
Inhaled nitric oxide and sildenafil therapy for a pediatric patient with multiple pulmonary arteriovenous malformations.
Arthritis
Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with
adjuvant arthritis
Arthritis
Treatment Algorithms in Systemic Lupus Erythematosus.
Asthma
A single dose of Sildenafil does not enhance FeNO: A randomised, cross-over and placebo-controlled study.
Asthma
[Cyclic nucleotides phosphodiesterase activity in a rat lung model of asthma]
Atherosclerosis
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.
Atherosclerosis
Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: the beneficial effects of sildenafil.
Atherosclerosis
Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study.
Atherosclerosis
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Atherosclerosis
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Atherosclerosis
Sildenafil (Viagra®) Prevents Cox-1/ TXA2 Pathway-Mediated Vascular Hypercontractility in ApoE-/- Mice.
Atrial Fibrillation
Application of Guideline-Based Echocardiographic Assessment of Left Atrial Pressure to Heart Failure with Preserved Ejection Fraction.
Autoimmune Diseases
Sildenafil Counteracts the In Vitro Activation of CXCL-9, CXCL-10 and CXCL-11/CXCR3 Axis Induced by Reactive Oxygen Species in Scleroderma Fibroblasts.
Azotemia
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
beta-Thalassemia
Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report.
Blindness
Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse.
Blindness
AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase.
Blindness
Apoptosis, retinitis pigmentosa, and degeneration.
Blindness
Exclusion of five subunits of cGMP phosphodiesterase in Leber's congenital amaurosis.
Blindness
Hippocampal synaptic plasticity in mice carrying the rd mutation in the gene encoding cGMP phosphodiesterase type 6 (PDE6).
Blindness
Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase.
Blindness
Retinal imaging in inherited retinal diseases.
Blindness
Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration.
Blister
The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis((R)) and the optical purity of tadalafil stereoisomers.
Brain Injuries
Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury.
Brain Injuries
Neuroprotective effects of tadalafil on gerbil dopaminergic neurons following cerebral ischemia.
Brain Injuries, Traumatic
Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury.
Brain Ischemia
Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage.
Brain Neoplasms
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Brain Neoplasms
Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.
Breast Neoplasms
Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells.
Breast Neoplasms
Exisulind Cell Pathways.
Breast Neoplasms
Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
Breast Neoplasms
Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.
Breast Neoplasms
Identification of a RAPD marker linked to progressive rod-cone degeneration in dogs.
Breast Neoplasms
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
Breast Neoplasms
Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.
Breast Neoplasms
Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.
Breast Neoplasms
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Breast Neoplasms
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.
Bronchopulmonary Dysplasia
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Bronchopulmonary Dysplasia
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Carcinogenesis
Erratum: Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Carcinogenesis
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Carcinogenesis
Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling.
Carcinogenesis
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Carcinoma
cGMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Carcinoma
Cyclic guanosine monophosphate phosphodiesterase activity in human gingival carcinoma.
Carcinoma
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Carcinoma
Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.
Carcinoma
Expression of iNOS--a favourable prognostic marker for early-stage carcinoma of the uterine cervix.
Carcinoma
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Carcinoma
The hypertensive effect of sorafenib is abolished by sildenafil.
Carcinoma
The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.
Carcinoma, Hepatocellular
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Carcinoma, Hepatocellular
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
Carcinoma, Papillary
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Carcinoma, Renal Cell
The hypertensive effect of sorafenib is abolished by sildenafil.
Carcinoma, Squamous Cell
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
Cardiomegaly
Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Cardiomegaly
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Cardiomegaly
An MRTF-A-Sp1-PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy.
Cardiomegaly
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Cardiomegaly
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Cardiomegaly
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Cardiomegaly
MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.
Cardiomegaly
Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic Peptide signaling.
Cardiomegaly
Phosphodiesterase 5 Associates With ?2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
Cardiomegaly
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.
Cardiomegaly
Pulmonary vascular and cardiac effects of peroxynitrite decomposition in newborn rats.
Cardiomegaly
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.
Cardiomegaly
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Cardiomegaly
Sildenafil and Cardioprotection.
Cardiomegaly
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
Cardiomegaly
The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38.
Cardiomegaly
Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy.
Cardiomyopathies
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Cardiomyopathies
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Cardiomyopathies
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Cardiomyopathies
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Cardiomyopathies
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Cardiomyopathies
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Cardiomyopathy, Hypertrophic
Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy.
Cardiotoxicity
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Cardiotoxicity
Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.
Cardiotoxicity
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
Cardiotoxicity
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Cardiovascular Diseases
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Cardiovascular Diseases
A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio(®) ) in cardiac surgery: the REVAKI-1 study.
Cardiovascular Diseases
Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model.
Cardiovascular Diseases
Cardiac uses of phosphodiesterase-5 inhibitors.
Cardiovascular Diseases
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Cardiovascular Diseases
Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor ?-induced Smad signaling.
Cardiovascular Diseases
E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against cardiovascular diseases.
Cardiovascular Diseases
Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Cardiovascular Diseases
Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.
Cardiovascular Diseases
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Cardiovascular Diseases
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference.
Cardiovascular Diseases
Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Cardiovascular Diseases
Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.
Cardiovascular Diseases
Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
Cardiovascular Diseases
Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.
Cardiovascular Diseases
Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents.
Cardiovascular Diseases
Local condiments from fermented tropical legume seeds modulate activities of critical enzymes relevant to cardiovascular diseases and endothelial function.
Cardiovascular Diseases
Modulatory effect of some citrus (Citrus limon, Citrus reticulata, Citrus maxima) peels on monoamine oxidase, phosphodiesterase-5 and angiotensin-1 converting enzyme activities in rat heart homogenate.
Cardiovascular Diseases
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.
Cardiovascular Diseases
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Cardiovascular Diseases
Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Cardiovascular Diseases
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine.
Cardiovascular Diseases
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Cardiovascular Diseases
Sexual activity and cardiovascular disease.
Cardiovascular Diseases
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Cardiovascular Diseases
The penis as a barometer of endothelial health.
Cardiovascular Diseases
The Phosphodiesterase-5 Inhibitor Vardenafil Improves the Activation of BMP Signaling in Response to Hydrogen Peroxide.
Cardiovascular Diseases
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Cardiovascular Diseases
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Cardiovascular Diseases
The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.
Cardiovascular Diseases
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.
Cardiovascular Diseases
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
Cardiovascular Diseases
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Cardiovascular Diseases
Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection.
Cardiovascular Diseases
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Cardiovascular Diseases
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Cardiovascular Diseases
Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Cardiovascular Diseases
[Cardiovascular disease and sexuality]
Cardiovascular Diseases
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Catalepsy
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Cataract
Nonarteritic anterior ischaemic optic neuropathy.
Central Serous Chorioretinopathy
Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study.
Central Serous Chorioretinopathy
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.
Central Serous Chorioretinopathy
Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
Central Serous Chorioretinopathy
THE EFFECTS OF SILDENAFIL CITRATE ON CHOROIDAL THICKNESS AS DETERMINED BY ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY.
Central Serous Chorioretinopathy
[Serous central chorioretinopathy and tadalafil: A case report.]
Cerebral Hemorrhage
A Case of Recurrent Lobar Intracerebral Hemorrhage in the Setting of Phosphodiesterase-5 Inhibitor Use.
Cholera
Functional modifications of transducin induced by cholera or pertussis-toxin-catalyzed ADP-ribosylation.
Cholera
Inhibition of guanylate cyclase and cyclic GMP phosphodiesterase by cholera toxin.
Cholera
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Cholera
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Ciliopathies
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Ciliopathies
Membrane protein transport in photoreceptors: the function of PDE?: the Proctor lecture.
Ciliopathies
Retinal remodeling.
Cluster Headache
Sildenafil can induce the onset of a cluster headache bout.
Cluster Headache
Sildenafil can trigger cluster headaches.
Colitis
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Colitis
The effect of phosphodiesterase-5 inhibition by sildenafil citrate on inflammation and apoptosis in rat experimental colitis.
Coloboma
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Colonic Neoplasms
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.
Colonic Neoplasms
Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer.
Colonic Neoplasms
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC.
Colonic Neoplasms
Phosphodiesterase-5 inhibitors for colon cancer chemoprevention.
Colonic Neoplasms
Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.
Colonic Neoplasms
The enduring promise of phosphodiesterase 5 inhibitors for colon cancer prevention.
Color Vision Defects
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
Color Vision Defects
A nonhuman primate model of inherited retinal disease.
Color Vision Defects
Characterization of Retinal Structure in ATF6-Associated Achromatopsia.
Color Vision Defects
Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identification of a new nonsense mutation in GNAT2 gene.
Color Vision Defects
Congenital Achromatopsia and Macular Atrophy Caused by a Novel Recessive PDE6C Mutation (p.E591K).
Color Vision Defects
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia.
Color Vision Defects
Deep Phenotyping of PDE6C-Associated Achromatopsia.
Color Vision Defects
Distinct patterns of compartmentalization and proteolytic stability of PDE6C mutants linked to achromatopsia.
Color Vision Defects
Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene.
Color Vision Defects
Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.
Color Vision Defects
Molecular Genetics of Achromatopsia in Newfoundland Reveal Genetic Heterogeneity, Founder Effects and the First Cases of Jalili Syndrome in North America.
Color Vision Defects
Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia.
Color Vision Defects
Novel Bi-allelic PDE6C Variant Leads to Congenital Achromatopsia.
Color Vision Defects
Novel mutations in the gene for ?-subunit of retinal cone cyclic nucleotide-gated channels in a Japanese patient with congenital achromatopsia.
Color Vision Defects
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Color Vision Defects
Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration.
Color Vision Defects
Two novel PDE6C gene mutations in Chinese family with achromatopsia.
Colorectal Neoplasms
No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction.
Colorectal Neoplasms
Phosphodiesterase 5 Inhibitor Use and Risk of Conventional and Serrated Precursors of Colorectal Cancer.
Colorectal Neoplasms
Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis.
Colorectal Neoplasms
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer.
Colorectal Neoplasms
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Colorectal Neoplasms
Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.
Colorectal Neoplasms
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Colorectal Neoplasms
The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
Colorectal Neoplasms
Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.
Coma
Potentially fatal new trend in performance enhancement: a cautionary note on nitrite.
Complex Regional Pain Syndromes
Effect of tadalafil on blood flow, pain, and function in chronic cold Complex Regional Pain Syndrome: a randomized controlled trial.
Cone Dystrophy
A substitution of G to C in the cone cGMP-phosphodiesterase gamma subunit gene found in a distinctive form of cone dystrophy.
Cone Dystrophy
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Cone-Rod Dystrophies
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B.
Cone-Rod Dystrophies
PDE6C: Novel Mutations, Atypical Phenotype, and Differences Among Children and Adults.
Cone-Rod Dystrophies
Retinal imaging in inherited retinal diseases.
Congenitally Corrected Transposition of the Great Arteries
Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and design.
Connective Tissue Diseases
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Connective Tissue Diseases
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Coronary Artery Disease
Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers.
Coronary Artery Disease
Effects of tadalafil on myocardial blood flow in patients with coronary artery disease.
Coronary Artery Disease
Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
Coronary Artery Disease
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Coronary Artery Disease
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
Coronary Artery Disease
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Coronary Artery Disease
Identification of a Functional PDE5A Variant at the Chromosome 4q27 Coronary Artery Disease Locus in an Extended Myocardial Infarction Family.
Coronary Artery Disease
Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease.
Coronary Artery Disease
Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease.
Coronary Artery Disease
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.
Coronary Artery Disease
Sexual function in patients with chronic angina pectoris.
Coronary Artery Disease
Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study.
Coronary Artery Disease
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Coronary Artery Disease
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
Coronary Artery Disease
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
Coronary Artery Disease
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Coronary Artery Disease
Vacuum Erection Devices Revisited: Its Emerging Role in the Treatment of Erectile Dysfunction and Early Penile Rehabilitation Following Prostate Cancer Therapy.
Coronary Artery Disease
Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.
Coronary Artery Disease
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
Coronary Disease
Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
Coronary Disease
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.
Coronary Disease
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Coronary Disease
Sildenafil: emerging cardiovascular indications.
Coronary Disease
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
Coronary Disease
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Coronary Disease
The Safety of Preoperative Vardenafil in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Coronary Disease
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Coronary Occlusion
Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
Coronary Thrombosis
Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition.
Coronary Thrombosis
Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
COVID-19
Addressing male sexual and reproductive health in the wake of COVID-19 outbreak.
COVID-19
Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).
COVID-19
Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
COVID-19
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
COVID-19
Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
COVID-19
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Cranial Nerve Diseases
A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
Cystic Fibrosis
Classical activation of macrophages and vardenafil.
Cystic Fibrosis
Inhaled PDE5 inhibitors restore chloride transport in cystic fibrosis mice.
Cystic Fibrosis
Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease?
Cystic Fibrosis
Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis.
Cystic Fibrosis
Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction.
Cystic Fibrosis
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.
Death, Sudden, Cardiac
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Dementia
Role of sildenafil in neurological disorders.
Dementia, Vascular
Ameliorative effect of Phosphodiesterase-5 inhibitor in Rat model of Vascular Dementia.
Dementia, Vascular
Sildenafil treatment of vascular dementia in aged rats.
Dementia, Vascular
Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia.
Demyelinating Diseases
Phosphodiesterase-5 inhibition promotes remyelination by MCP-1/CCR-2 and MMP-9 regulation in a cuprizone-induced demyelination model.
Dermatitis, Atopic
Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
Diabetes Mellitus
Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Diabetes Mellitus
Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis.
Diabetes Mellitus
Current diagnosis and management of erectile dysfunction.
Diabetes Mellitus
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Diabetes Mellitus
Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction.
Diabetes Mellitus
Effect of phosphodiesterase-5 inhibitors on glycemic control in person with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Diabetes Mellitus
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Diabetes Mellitus
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Diabetes Mellitus
Management of erectile dysfunction.
Diabetes Mellitus
Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Diabetes Mellitus
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Diabetes Mellitus
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Diabetes Mellitus
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Diabetes Mellitus
Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Diabetes Mellitus
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial.
Diabetes Mellitus
Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men.
Diabetes Mellitus
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Diabetes Mellitus
The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis.
Diabetes Mellitus
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Diabetes Mellitus
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Diabetes Mellitus
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
Diabetes Mellitus, Experimental
Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
Diabetes Mellitus, Experimental
The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction.
Diabetes Mellitus, Type 1
Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Diabetes Mellitus, Type 2
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes.
Diabetes Mellitus, Type 2
Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of phosphodiesterase-5 inhibitors on glycemic control in person with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus, Type 2
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
Diabetes Mellitus, Type 2
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Diabetes Mellitus, Type 2
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
Diabetes Mellitus, Type 2
Testosterone therapy for sexual dysfunction in men with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Diabetes Mellitus, Type 2
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Diabetic Cardiomyopathies
Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.
Diabetic Cardiomyopathies
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition.
Diabetic Cardiomyopathies
Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.
Diabetic Cardiomyopathies
The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence.
Diabetic Foot
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
Diabetic Nephropathies
Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.
Diabetic Nephropathies
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.
Diabetic Nephropathies
Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.
Diabetic Nephropathies
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.
Diabetic Nephropathies
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats.
Diabetic Neuropathies
Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
Diabetic Neuropathies
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
Diabetic Neuropathies
Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor.
Down Syndrome
Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
Drug-Related Side Effects and Adverse Reactions
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Drug-Related Side Effects and Adverse Reactions
ADMET considerations for phosphodiesterase-5 inhibitors.
Drug-Related Side Effects and Adverse Reactions
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Drug-Related Side Effects and Adverse Reactions
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
Drug-Related Side Effects and Adverse Reactions
Side effects reported by European consumers for medications for erectile dysfunction.
Dyskinesias
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Dyslipidemias
Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study.
Dyslipidemias
Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Dyslipidemias
Vardenafil in men with stable statin therapy and dyslipidemia.
Dyspnea
Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus.
Dyspnea
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Eisenmenger Complex
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Eisenmenger Complex
Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study.
Eisenmenger Complex
Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors.
Eisenmenger Complex
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Embolic Stroke
Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.
Embolic Stroke
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Encephalomyelitis
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Encephalomyelitis
Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord.
Encephalomyelitis, Autoimmune, Experimental
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Encephalomyelitis, Autoimmune, Experimental
Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord.
Epilepsy
Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model.
Epilepsy
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Epistaxis
Epistaxis after PDE-5 inhibitors misuse.
Epistaxis
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Erectile Dysfunction
"Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.
Erectile Dysfunction
3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.
Erectile Dysfunction
3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Erectile Dysfunction
8-Aryl xanthines potent inhibitors of phosphodiesterase 5.
Erectile Dysfunction
A "real life" investigation on the prescriptive habits among Italian andrologists: The "CONSER" survey from Italian Society of Andrology (SIA) on Sildenafil oral film.
Erectile Dysfunction
A 6-Month, Prospective, Observational Study of PDE5 Inhibitor Treatment Persistence and Adherence in Latin American Men with Erectile Dysfunction.
Erectile Dysfunction
A case of acute pulmonary thromboembolism after taking tadalafil.
Erectile Dysfunction
A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.
Erectile Dysfunction
A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
Erectile Dysfunction
A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.
Erectile Dysfunction
A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry.
Erectile Dysfunction
A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With ?-Blockers and ?-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction.
Erectile Dysfunction
A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations.
Erectile Dysfunction
A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction.
Erectile Dysfunction
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
Erectile Dysfunction
A multifaceted approach to maximize erectile function and vascular health.
Erectile Dysfunction
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
Erectile Dysfunction
A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
Erectile Dysfunction
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Erectile Dysfunction
A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide.
Erectile Dysfunction
A novel aphrodisiac compound from an orchid that activates nitric oxide synthases.
Erectile Dysfunction
A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method.
Erectile Dysfunction
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
Erectile Dysfunction
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.
Erectile Dysfunction
A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
Erectile Dysfunction
A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers.
Erectile Dysfunction
A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.
Erectile Dysfunction
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Erectile Dysfunction
A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction.
Erectile Dysfunction
A protein tyrosine kinase inhibitor, imatinib mesylate (gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.
Erectile Dysfunction
A Proteomic Analysis Using an Animal Model for Hyperlipidemia-related Erectile Dysfunction.
Erectile Dysfunction
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction.
Erectile Dysfunction
A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction.
Erectile Dysfunction
A study of the management of erectile dysfunction in general practice.
Erectile Dysfunction
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Erectile Dysfunction
A Systematic Review Assessing the Economic Impact of Sildenafil Citrate (Viagra(®) ) in the Treatment of Erectile Dysfunction.
Erectile Dysfunction
A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
Erectile Dysfunction
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Erectile Dysfunction
Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices.
Erectile Dysfunction
ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.
Erectile Dysfunction
Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Erectile Dysfunction
Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients.
Erectile Dysfunction
Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes.
Erectile Dysfunction
Acute dysphonia secondary to vocal fold hemorrhage after vardenafil use.
Erectile Dysfunction
Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction.
Erectile Dysfunction
Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study.
Erectile Dysfunction
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Erectile Dysfunction
Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Erectile Dysfunction
Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?
Erectile Dysfunction
Adulteration of herbal sexual enhancers and slimmers: The wish for better sexual well-being and perfect body can be risky.
Erectile Dysfunction
Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don't Work.
Erectile Dysfunction
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.
Erectile Dysfunction
Age at First Presentation for Erectile Dysfunction: Analysis of Changes over a 12-yr Period.
Erectile Dysfunction
Aggressive behavior increases after termination of chronic sildenafil treatment in mice.
Erectile Dysfunction
Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors.
Erectile Dysfunction
Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats.
Erectile Dysfunction
An algorithm for medical management in male lower urinary tract symptoms.
Erectile Dysfunction
An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
Erectile Dysfunction
An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.
Erectile Dysfunction
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
Erectile Dysfunction
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
Erectile Dysfunction
An open trial of oral sildenafilin antidepressant-induced sexual dysfunction.
Erectile Dysfunction
An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.
Erectile Dysfunction
An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
Erectile Dysfunction
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
Erectile Dysfunction
An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
Erectile Dysfunction
An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
Erectile Dysfunction
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
An update on the drug safety of treating erectile dysfunction.
Erectile Dysfunction
Analysis of pharmacological mechanisms of Yinyanghuo as treatment of erectile dysfunction with network pharmacology-based strategy.
Erectile Dysfunction
Androgen deficiency in the etiology and treatment of erectile dysfunction.
Erectile Dysfunction
Animal models in urological disease and sexual dysfunction.
Erectile Dysfunction
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Erectile Dysfunction
Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.
Erectile Dysfunction
Application of high-performance liquid chromatography with charged aerosol detection for universal quantitation of undeclared phosphodiesterase-5 inhibitors in herbal dietary supplements.
Erectile Dysfunction
Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction.
Erectile Dysfunction
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
Erectile Dysfunction
Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature.
Erectile Dysfunction
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Erectile Dysfunction
Arterial erectile dysfunction: Different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil.
Erectile Dysfunction
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach.
Erectile Dysfunction
Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice.
Erectile Dysfunction
Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States.
Erectile Dysfunction
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Erectile Dysfunction
Assessment of the effect of mirodenafil on the hemodynamics of healthy male korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Erectile Dysfunction
Assessment of the Efficacy of Combination Therapy with Folic Acid and Tadalafil for the Management of Erectile Dysfunction in Men with Type 2 Diabetes Mellitus.
Erectile Dysfunction
Assisted semen collection using two phosphodiesterase type 5 inhibitors (Tadalafil and Sildenafil) in infertile men with mild erectile dysfunction.
Erectile Dysfunction
Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Erectile Dysfunction
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
Erectile Dysfunction
Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
Erectile Dysfunction
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Erectile Dysfunction
Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction.
Erectile Dysfunction
Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction.
Erectile Dysfunction
Avanafil - a further step to tailoring patient needs and expectations.
Erectile Dysfunction
Avanafil for male erectile dysfunction: a systematic review and meta-analysis.
Erectile Dysfunction
Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Erectile Dysfunction
Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Erectile Dysfunction
Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles in retinal function and hemodynamics in anesthetized dogs.
Erectile Dysfunction
Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Erectile Dysfunction
Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Erectile Dysfunction
Avanafil: a review of its use in patients with erectile dysfunction.
Erectile Dysfunction
BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo.
Erectile Dysfunction
Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Benefits of erectile function recovery programs after radical prostatectomy (Review).
Erectile Dysfunction
Bilateral neurosensory retinal detachment secondary to tadalafil treatment.
Erectile Dysfunction
Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.
Erectile Dysfunction
Bioequivalence study of sildenafil citrate tablets in healthy human volunteers.
Erectile Dysfunction
Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices.
Erectile Dysfunction
Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials.
Erectile Dysfunction
Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction.
Erectile Dysfunction
Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?
Erectile Dysfunction
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
Erectile Dysfunction
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Erectile Dysfunction
Cardioprotection with sildenafil: implications for clinical practice.
Erectile Dysfunction
Cardiovascular effects of phosphodiesterase 5 inhibitors.
Erectile Dysfunction
Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5).
Erectile Dysfunction
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
Erectile Dysfunction
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Erectile Dysfunction
Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Erectile Dysfunction
Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Erectile Dysfunction
Cardiovascular Risk Factors Determine Erectile and Arterial Function Response to Sildenafil.
Erectile Dysfunction
Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market.
Erectile Dysfunction
Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Erectile Dysfunction
Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors.
Erectile Dysfunction
Cavernous body reduction in four patients with erectile dysfunction due to insufficient venous occlusion and a deficit of elastic fibers in the tunica albuginea.
Erectile Dysfunction
cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil.
Erectile Dysfunction
Central serous chorioretinopathy due to tadalafil use.
Erectile Dysfunction
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
Erectile Dysfunction
Challenges in sexual medicine.
Erectile Dysfunction
Change of Erectile Function and Responsiveness to Phosphodiesterase Type 5 Inhibitors at Different Stages of Streptozotocin-Induced Diabetes in Rats.
Erectile Dysfunction
Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
Erectile Dysfunction
Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Erectile Dysfunction
Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes.
Erectile Dysfunction
Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.
Erectile Dysfunction
Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Erectile Dysfunction
Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
Erectile Dysfunction
Chronic Vardenafil Treatment Improves Erectile Function via Structural Maintenance of Penile Corpora Cavernosa in Rats with Acute Arteriogenic Erectile Dysfunction.
Erectile Dysfunction
Classical activation of macrophages and vardenafil.
Erectile Dysfunction
Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients.
Erectile Dysfunction
Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Erectile Dysfunction
Clinical monograph for drug formulary review: erectile dysfunction agents.
Erectile Dysfunction
Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.
Erectile Dysfunction
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Clinical use of sildenafil in pulmonary artery hypertension.
Erectile Dysfunction
Coital hemorrhage of an arteriovenous malformation after premedication with tadalafil (cialis).
Erectile Dysfunction
Color Doppler Duplex Ultrasound (CDDU) Parameters in Men without Organic Erectile Dysfunction.
Erectile Dysfunction
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Erectile Dysfunction
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum.
Erectile Dysfunction
Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue.
Erectile Dysfunction
Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Erectile Dysfunction
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction.
Erectile Dysfunction
Combination of Psychological Intervention and Phosphodiesterase-5 Inhibitors for Erectile Dysfunction: A Narrative Review and Meta-Analysis.
Erectile Dysfunction
Combination of stromal vascular fraction and Ad-COMP-Ang1 gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction.
Erectile Dysfunction
Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
Erectile Dysfunction
Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil.
Erectile Dysfunction
Combination therapy for erectile dysfunction: an update review.
Erectile Dysfunction
Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
Erectile Dysfunction
Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study.
Erectile Dysfunction
Comment on "Efficacy and safety of oral phosphodiesterase 5 inhibitor for erectile dysfunction: a network meta-analysis and multicriteria decision".
Erectile Dysfunction
Comorbid LUTS and erectile dysfunction: optimizing their management.
Erectile Dysfunction
Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis.
Erectile Dysfunction
Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction.
Erectile Dysfunction
Comparative effects of sildenafil, phentolamine, yohimbine and L-arginine on the rabbit corpus cavernosum.
Erectile Dysfunction
Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Erectile Dysfunction
Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Erectile Dysfunction
Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Erectile Dysfunction
Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.
Erectile Dysfunction
Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials.
Erectile Dysfunction
Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor Tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Erectile Dysfunction
Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Erectile Dysfunction
Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction against upregulated cavernosal NADPH oxidase, protein kinase C?, and endothelin system in diabetic rats.
Erectile Dysfunction
Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Erectile Dysfunction
Compliance with Testosterone Replacement Therapy in Patients with Testosterone Deficiency Syndrome: A 10-Year Observational Study in Korea.
Erectile Dysfunction
Computational Analysis of the Mechanism and Thermodynamics of Inhibition of Phosphodiesterase 5A by Synthetic Ligands.
Erectile Dysfunction
Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5.
Erectile Dysfunction
Condom Attitudes of Heterosexual Men Ages 50 and Older Using Prescribed Drugs (Viagra, Cialis, Levitra) to Treat Erectile Dysfunction.
Erectile Dysfunction
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
Erectile Dysfunction
Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction.
Erectile Dysfunction
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Erectile Dysfunction
Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil.
Erectile Dysfunction
Correlations With Satisfaction Measures in Men Treated With Phosphodiesterase Inhibitors for Erectile Dysfunction.
Erectile Dysfunction
Counseling patients about sexual issues.
Erectile Dysfunction
Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.
Erectile Dysfunction
Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Erectile Dysfunction
Current and Emerging Treatments for Premature Ejaculation.
Erectile Dysfunction
Current concepts in the evaluation and management of erectile dysfunction.
Erectile Dysfunction
Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.
Erectile Dysfunction
Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis.
Erectile Dysfunction
Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
Erectile Dysfunction
DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats.
Erectile Dysfunction
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
Erectile Dysfunction
Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels.
Erectile Dysfunction
Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Erectile Dysfunction
Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse.
Erectile Dysfunction
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS-application to forensic and therapeutic drug monitoring cases.
Erectile Dysfunction
Determination of Phosphodiesterase-5 Inhibitors and Analogs Using High-Performance Liquid Chromatography with Ultraviolet Detection.
Erectile Dysfunction
Determination of sildenafil by preconcentration on surfactant coated polymeric resin followed by spectrofluorimetry.
Erectile Dysfunction
Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection.
Erectile Dysfunction
Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study.
Erectile Dysfunction
Development and evaluation of an immunochromatographic strip for rapid screening of sildenafil-type compounds as illegal additives in functional foods.
Erectile Dysfunction
Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction.
Erectile Dysfunction
Development and validation of a dissolution test for lodenafil carbonate based on in vivo data.
Erectile Dysfunction
Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood.
Erectile Dysfunction
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Erectile Dysfunction
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Erectile Dysfunction
Development of a group-specific antibody-based immunoassay method for simultaneously detecting sildenafil-like adulterants in herbal spirit drinks.
Erectile Dysfunction
Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody.
Erectile Dysfunction
Development of an optimized avanafil-loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation.
Erectile Dysfunction
Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study.
Erectile Dysfunction
Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats.
Erectile Dysfunction
Diabetes and Sexuality.
Erectile Dysfunction
Diabetes Exacerbates the Functional Deficiency of NO/cGMP Pathway Associated with Erectile Dysfunction in Human Corpus Cavernosum and Penile Arteries.
Erectile Dysfunction
Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research.
Erectile Dysfunction
Diagnosis and management of erectile dysfunction in the primary care setting.
Erectile Dysfunction
Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk.
Erectile Dysfunction
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Erectile Dysfunction
Differentiation of human neuroblastoma cell line IMR-32 by sildenafil and its newly discovered analogue IS00384.
Erectile Dysfunction
Direct androgen regulation of PDE5 gene or the lack thereof.
Erectile Dysfunction
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats.
Erectile Dysfunction
Direct-To-Consumer Internet Prescription Platforms Overlook Crucial Pathology Found During Traditional Office Evaluation of Young Men With Erectile Dysfunction.
Erectile Dysfunction
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Erectile Dysfunction
Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.
Erectile Dysfunction
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Erectile Dysfunction
Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis.
Erectile Dysfunction
Docking-based CoMFA and CoMSIA analyses of tetrahydro-?-carboline derivatives as type-5 phosphodiesterase inhibitors.
Erectile Dysfunction
Does Current Scientific and Clinical Evidence Support the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Premature Ejaculation? A Systematic Review and Meta-analysis.
Erectile Dysfunction
Does educational status affect a patient's behavior toward erectile dysfunction?
Erectile Dysfunction
Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study.
Erectile Dysfunction
Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
Erectile Dysfunction
Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A pilot study.
Erectile Dysfunction
Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation.
Erectile Dysfunction
Drug combinations in the therapy of low response to phosphodiesterase 5 inhibitors in patients with erectile dysfunction.
Erectile Dysfunction
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
Erectile Dysfunction
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Erectile Dysfunction
Early administration of phosphodiesterase 5 inhibitors after induction of diabetes in a rat model may prevent erectile dysfunction.
Erectile Dysfunction
Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
Erectile Dysfunction
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction.
Erectile Dysfunction
Editorial comment on: chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction.
Erectile Dysfunction
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
Erectile Dysfunction
Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction.
Erectile Dysfunction
Effect of BKCa Channel Opener LDD175 on Erectile Function in an In Vivo Diabetic Rat Model.
Erectile Dysfunction
Effect of Chronic Administration of PDE5 Combined with Glycemic Control on Erectile Function in Streptozotocin-Induced Diabetic Rats.
Erectile Dysfunction
Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice.
Erectile Dysfunction
Effect of DA-8159, a selective phosphodiesterase type 5 inhibitor, on electroretinogram and retinal histology in rabbits.
Erectile Dysfunction
Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction.
Erectile Dysfunction
Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.
Erectile Dysfunction
Effect of Intracavernous Administration of Angiopoietin-4 on Erectile Function in the Streptozotocin-Induced Diabetic Mouse.
Erectile Dysfunction
Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
Erectile Dysfunction
Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical Prostatectomy.
Erectile Dysfunction
Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study.
Erectile Dysfunction
Effect of phosphodiesterase-5 inhibitor on hearing.
Erectile Dysfunction
Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Erectile Dysfunction
Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis.
Erectile Dysfunction
Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study.
Erectile Dysfunction
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Erectile Dysfunction
Effect of sildenafil in cavernous arteries of patients with erectile dysfunction.
Erectile Dysfunction
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Erectile Dysfunction
Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats.
Erectile Dysfunction
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.
Erectile Dysfunction
Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.
Erectile Dysfunction
Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog.
Erectile Dysfunction
Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury.
Erectile Dysfunction
Effectiveness of Intracavernous Delivery of Recombinant Human Hepatocyte Growth Factor on Erectile Function in the Streptozotocin-Induced Diabetic Mouse.
Erectile Dysfunction
Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
Erectile Dysfunction
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Erectile Dysfunction
Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats.
Erectile Dysfunction
Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial.
Erectile Dysfunction
Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.
Erectile Dysfunction
Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action.
Erectile Dysfunction
Effects of Once-Daily Tadalafil on Treatment Satisfaction, Psychosocial Outcomes, Spontaneous Erections, and Measures of Endothelial Function in Men With Erectile Dysfunction But Naive to Phosphodiesterase Type 5 Inhibitors.
Erectile Dysfunction
Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Erectile Dysfunction
Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
Erectile Dysfunction
Effects of sildenafil citrate on human hemodynamics.
Erectile Dysfunction
Effects of sildenafil citrate on peripheral fatigue and exercise performance after exhaustive swimming exercise in rats.
Erectile Dysfunction
Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue.
Erectile Dysfunction
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation.
Erectile Dysfunction
Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats.
Erectile Dysfunction
Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.
Erectile Dysfunction
Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
Erectile Dysfunction
Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.
Erectile Dysfunction
Effects of systemic tadalafil on skin flap survival in rats.
Erectile Dysfunction
Effects of tadalafil on myocardial blood flow in patients with coronary artery disease.
Erectile Dysfunction
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Erectile Dysfunction
Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study.
Erectile Dysfunction
Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Erectile Dysfunction
Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial.
Erectile Dysfunction
Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
Erectile Dysfunction
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Erectile Dysfunction
Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.
Erectile Dysfunction
Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Erectile Dysfunction
Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
Erectile Dysfunction
Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction.
Erectile Dysfunction
Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications.
Erectile Dysfunction
Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction.
Erectile Dysfunction
Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study.
Erectile Dysfunction
Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men.
Erectile Dysfunction
Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Erectile Dysfunction
Efficacy and Safety of Oral Mirodenafil in the Treatment of Erectile Dysfunction in Diabetic Men in Korea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Erectile Dysfunction
Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Erectile Dysfunction
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial.
Erectile Dysfunction
Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Erectile Dysfunction
Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
Erectile Dysfunction
Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
Erectile Dysfunction
Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction.
Erectile Dysfunction
Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
Erectile Dysfunction
Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.
Erectile Dysfunction
Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies.
Erectile Dysfunction
Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study.
Erectile Dysfunction
Efficacy and Safety of Tadalafil for Erectile Dysfunction in Patients with Multiple Sclerosis.
Erectile Dysfunction
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.
Erectile Dysfunction
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
Erectile Dysfunction
Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Erectile Dysfunction
Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Erectile Dysfunction
Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Erectile Dysfunction
Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial.
Erectile Dysfunction
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
Erectile Dysfunction
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction.
Erectile Dysfunction
Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study.
Erectile Dysfunction
Efficacy of Phosphodiesterase Type 5 Inhibitor Treatment in Men with Erectile Dysfunction and Dyslipidemia: A Post Hoc Analysis of the Vardenafil Statin Study.
Erectile Dysfunction
Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Erectile Dysfunction
Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled Trial.
Erectile Dysfunction
Efficiency of combined therapy with impaza and type 5 phosphodiesterase inhibitors in prophylactics of posttraumatic erectile dysfunction.
Erectile Dysfunction
Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism.
Erectile Dysfunction
Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome.
Erectile Dysfunction
Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.
Erectile Dysfunction
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Erectile Dysfunction
Emerging pharmacologic approaches for the treatment of lower urinary tract disorders.
Erectile Dysfunction
Endothelial Antioxidant Administration Ameliorates the Erectile Response to PDE5 Regardless of the Extension of the Atherosclerotic Process.
Erectile Dysfunction
Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives.
Erectile Dysfunction
Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage.
Erectile Dysfunction
Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats.
Erectile Dysfunction
Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs.
Erectile Dysfunction
Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats.
Erectile Dysfunction
Enzyme activities of the nitric oxide-cGMP pathway in corpus cavernosum isolated from middle-aged rats.
Erectile Dysfunction
Erectile Dysfunction (ED) is a Shared Sexual Concern of Couples II: Association of Female Partner Characteristics with Male Partner ED Treatment Seeking and Phosphodiesterase Type 5 Inhibitor Utilization.
Erectile Dysfunction
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Erectile Dysfunction
Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Erectile Dysfunction
Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment.
Erectile Dysfunction
Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Erectile Dysfunction
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men.
Erectile Dysfunction
Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Erectile Dysfunction
Erectile dysfunction in aging men: testosterone role in therapeutic protocols.
Erectile Dysfunction
Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice.
Erectile Dysfunction
Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Erectile Dysfunction
Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies.
Erectile Dysfunction
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Erectile Dysfunction
Erectile dysfunction.
Erectile Dysfunction
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Erectile Dysfunction
Erectile dysfunction: etiology, evaluation, and treatment options.
Erectile Dysfunction
Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.
Erectile Dysfunction
Erectile dysfunction: monitoring response to treatment in clinical practice--recommendations of an international study panel.
Erectile Dysfunction
Erectile dysfunction: the role of penile Doppler ultrasound in diagnosis.
Erectile Dysfunction
Erectile dysfunctions.
Erectile Dysfunction
Erectile function after treatment for rhabdomyosarcoma of prostate and bladder.
Erectile Dysfunction
Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.
Erectile Dysfunction
Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.
Erectile Dysfunction
Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.
Erectile Dysfunction
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
Erectile Dysfunction
Evaluation of neuroprotective and anti-fatigue effects of sildenafil.
Erectile Dysfunction
Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos.
Erectile Dysfunction
Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Erectile Dysfunction
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
Erectile Dysfunction
Evaluation of therapeutic response of patients with erectile dysfunction.
Erectile Dysfunction
Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?
Erectile Dysfunction
Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors.
Erectile Dysfunction
Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction.
Erectile Dysfunction
Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Erectile Dysfunction
Exploring the potentials of some compounds from Garcinia kola seeds towards identification of novel PDE-5 inhibitors in erectile dysfunction therapy.
Erectile Dysfunction
Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Erectile Dysfunction
Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.
Erectile Dysfunction
Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously Hypertensive Rats Through Penile Tissue Remodeling and Neovascularization.
Erectile Dysfunction
Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.
Erectile Dysfunction
Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation.
Erectile Dysfunction
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Erectile Dysfunction
Factors predicting outcomes of penile rehabilitation with udenafil 50?mg following radical prostatectomy.
Erectile Dysfunction
Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Erectile Dysfunction
Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges.
Erectile Dysfunction
Fertility in men with spinal cord injury.
Erectile Dysfunction
Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry.
Erectile Dysfunction
Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.
Erectile Dysfunction
FR226807: a potent and selective phosphodiesterase type 5 inhibitor.
Erectile Dysfunction
Future prospects in the treatment of erectile dysfunction: focus on avanafil.
Erectile Dysfunction
Gender differences and dose proportionality in the toxicokinetics of udenafil and its active metabolite following oral administration in rodents.
Erectile Dysfunction
Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Erectile Dysfunction
Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis.
Erectile Dysfunction
Ginseng for erectile dysfunction.
Erectile Dysfunction
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
Erectile Dysfunction
Hemodynamic effects of sildenafil in patients with stable ischemic heart disease.
Erectile Dysfunction
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Erectile Dysfunction
Hepatoprotective role of vardenafil against experimentally induced hepatitis in mice.
Erectile Dysfunction
Herb-drug interaction of Epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats.
Erectile Dysfunction
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
Erectile Dysfunction
Histopathologic effect of chronic use of sildenafil citrate on the choroid & retina in male rats.
Erectile Dysfunction
Histopathologic results of long-term sildenafil administration on rat inner ear.
Erectile Dysfunction
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians.
Erectile Dysfunction
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.
Erectile Dysfunction
Hydrogen Sulfide and Urogenital Tract.
Erectile Dysfunction
Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study).
Erectile Dysfunction
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Erectile Dysfunction
Icariin modulates eNOS activity via effect on post-translational protein-protein interactions to improve erectile function of spontaneously hypertensive rats.
Erectile Dysfunction
Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
Erectile Dysfunction
Identification of Erectile Dysfunction Drugs in Dietary Supplements by Liquid Chromatography Ion Trap Mass Spectrometry.
Erectile Dysfunction
Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column.
Erectile Dysfunction
Immunolocalization of multidrug resistance protein 5 in the human genitourinary system.
Erectile Dysfunction
Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care.
Erectile Dysfunction
Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunction.
Erectile Dysfunction
Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population.
Erectile Dysfunction
Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue.
Erectile Dysfunction
Improved Sexual Function with Testosterone Replacement Therapy in Hypogonadal Men: Real-World Data from the Testim Registry in the United States (TRiUS).
Erectile Dysfunction
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.
Erectile Dysfunction
Improvement in symptoms of peripheral arterial disease with sildenafil therapy.
Erectile Dysfunction
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Erectile Dysfunction
Improvement of Sexual and Reproductive Function in Men with Spinal Cord Lesion.
Erectile Dysfunction
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being.
Erectile Dysfunction
In Vitro Fertilization Entails a High Prevalence of Erectile and Male Sexual Dysfunction: A Prospective Case-Control Study.
Erectile Dysfunction
In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect.
Erectile Dysfunction
In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Erectile Dysfunction
Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Erectile Dysfunction
Increased Phosphodiesterase Type 5 Levels in a Mouse Model of Type 2 Diabetes Mellitus.
Erectile Dysfunction
Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Inflatable penile prostheses for the treatment of erectile dysfunction.
Erectile Dysfunction
Influence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events.
Erectile Dysfunction
Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.
Erectile Dysfunction
Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Influence of the PDE5 inhibitor tadalafil on redox status and antioxidant defense system in C2C12 skeletal muscle cells.
Erectile Dysfunction
Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
Erectile Dysfunction
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.
Erectile Dysfunction
Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.
Erectile Dysfunction
Inhibition of proNGF and p75NTR Pathway Restores Erectile Function Through Dual Angiogenic and Neurotrophic Effects in the Diabetic Mouse.
Erectile Dysfunction
Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Erectile Dysfunction
Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves.
Erectile Dysfunction
Instrumental neutron activation analysis (INAA) and liquid chromatography (LC) coupled to high resolution mass spectrometry (HRMS) characterisation of sildenafil based products seized on the Italian illegal market.
Erectile Dysfunction
Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells.
Erectile Dysfunction
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Erectile Dysfunction
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Erectile Dysfunction
Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease.
Erectile Dysfunction
Interventions for sexual dysfunction following treatments for cancer.
Erectile Dysfunction
Intracavernosal injections in the diagnosis and treatment of PDE-5 resistant erectile dysfunction.
Erectile Dysfunction
Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse.
Erectile Dysfunction
Intracavernous delivery of freshly isolated stromal vascular fraction rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse.
Erectile Dysfunction
Intracavernous Delivery of Synthetic Angiopoietin-1 Protein as a Novel Therapeutic Strategy for Erectile Dysfunction in the Type II Diabetic db/db Mouse.
Erectile Dysfunction
Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment.
Erectile Dysfunction
Intracavernous pharmacotherapy for erectile dysfunction.
Erectile Dysfunction
Investigation of the Presence of Sildenafil in Herbal Dietary Supplements by Validated HPLC Method.
Erectile Dysfunction
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Ion beam analysis (IBA) and instrumental neutron activation analysis (INAA) for forensic characterisation of authentic Viagra® and of sildenafil-based illegal products.
Erectile Dysfunction
Is Inhibition of Phosphodiesterase Type-5 by Sildenafil a Promising Therapy for Volume Overload Heart Failure?
Erectile Dysfunction
Is Penile Length a Factor in Treatment of Erectile Dysfunction with PDE-5 Inhibitor?
Erectile Dysfunction
Is sex only for the healthy and wealthy?
Erectile Dysfunction
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Erectile Dysfunction
Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
Erectile Dysfunction
Isolation of two isoforms of phosphodiesterase 5 from rat penis.
Erectile Dysfunction
JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
Erectile Dysfunction
Key features for designing phosphodiesterase-5 inhibitors.
Erectile Dysfunction
l-Cys/CSE/H2S pathway modulates mouse uterus motility and sildenafil effect.
Erectile Dysfunction
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Erectile Dysfunction
Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Erectile Dysfunction
Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction.
Erectile Dysfunction
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Erectile Dysfunction
Letter to the Editor RE: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors.
Erectile Dysfunction
Lingual mucosal graft in treatment of Peyronie disease.
Erectile Dysfunction
Literature commentary.
Erectile Dysfunction
Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders.
Erectile Dysfunction
Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal.
Erectile Dysfunction
Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).
Erectile Dysfunction
Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
Erectile Dysfunction
Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Erectile Dysfunction
Low-Intensity Extracorporeal Shock Wave as a Novel Treatment for Erectile Dysfunction.
Erectile Dysfunction
Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors.
Erectile Dysfunction
Low-Intensity Shock Wave Therapy and Its Application to Erectile Dysfunction.
Erectile Dysfunction
Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment.
Erectile Dysfunction
Lower urinary tract symptoms and sexual dysfunction: a common approach.
Erectile Dysfunction
Lower urinary tract symptoms in men.
Erectile Dysfunction
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Male fertility following spinal cord injury: an update.
Erectile Dysfunction
Management of sildenafil treatment failures.
Erectile Dysfunction
Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach.
Erectile Dysfunction
Managing the adverse effects of radiation therapy.
Erectile Dysfunction
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Erectile Dysfunction
Medical therapy for benign prostatic hyperplasia: a review.
Erectile Dysfunction
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Erectile Dysfunction
Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Medicinal Plants Used for the Treatment of Erectile Dysfunction in Ethiopia: A Systematic Review.
Erectile Dysfunction
Melanocortins in the treatment of male and female sexual dysfunction.
Erectile Dysfunction
Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Erectile Dysfunction
Metabotropic Glutamate Receptor Subtype 7 Is Essential for Ejaculation.
Erectile Dysfunction
Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study.
Erectile Dysfunction
Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.
Erectile Dysfunction
Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.
Erectile Dysfunction
Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.
Erectile Dysfunction
Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment.
Erectile Dysfunction
Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study.
Erectile Dysfunction
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.
Erectile Dysfunction
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
Erectile Dysfunction
Multiple roles of the messenger molecule cGMP in testicular function.
Erectile Dysfunction
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Erectile Dysfunction
N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Erectile Dysfunction
Nasal congestion after visual sexual stimulation with and without sildenafil (Viagra): a randomized placebo-controlled study.
Erectile Dysfunction
NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
Erectile Dysfunction
Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.
Erectile Dysfunction
Neurogenic Sexual Dysfunction Treatment: A Systematic Review.
Erectile Dysfunction
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.
Erectile Dysfunction
New oral drugs for erectile dysfunction.
Erectile Dysfunction
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Erectile Dysfunction
New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is).
Erectile Dysfunction
Newer phosphodiesterase inhibitors: comparison with established agents.
Erectile Dysfunction
No adverse hemodynamic interaction between sildenafil and red wine.
Erectile Dysfunction
No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction.
Erectile Dysfunction
Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Erectile Dysfunction
Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.
Erectile Dysfunction
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Erectile Dysfunction
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Erectile Dysfunction
Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress.
Erectile Dysfunction
Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
Erectile Dysfunction
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Erectile Dysfunction
Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.
Erectile Dysfunction
Off-Label Use of Phosphodiesterase Type 5 Inhibitor Erectile Dysfunction Medication to Enhance Sex Among Gay and Bisexual Men in Australia: Results From the FLUX Study.
Erectile Dysfunction
Optic atrophy after sildenafil use.
Erectile Dysfunction
Optical coherence tomography in tadalafil-associated retinal toxicity.
Erectile Dysfunction
Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation.
Erectile Dysfunction
Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health.
Erectile Dysfunction
Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study.
Erectile Dysfunction
Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction.
Erectile Dysfunction
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Erectile Dysfunction
Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.
Erectile Dysfunction
Oral phosphodiesterase-5 inhibitors and sperm functions.
Erectile Dysfunction
Oral Testofen, L-Citrulline, Resveratrol, and Caffeine Supplement Drink Improves Sexual Function in Men with Phosphodiesterase 5 Inhibitors: Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study.
Erectile Dysfunction
Osteopathic approach to sexual dysfunction: holistic care to improve patient satisfaction and prevent mortality and morbidity.
Erectile Dysfunction
Overall cardiovascular profile of sildenafil citrate.
Erectile Dysfunction
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Erectile Dysfunction
Oxytocin is involved in the proconvulsant effects of Sildenafil: Possible role of CREB.
Erectile Dysfunction
Oxytocinergic system mediates the proconvulsant effects of sildenafil: The role of calcineurin.
Erectile Dysfunction
P144, A TGF-?1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.
Erectile Dysfunction
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.
Erectile Dysfunction
Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their sexual partners know?
Erectile Dysfunction
Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Erectile Dysfunction
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Erectile Dysfunction
PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.
Erectile Dysfunction
PDE-5 inhibitors for erectile dysfunction in men with diabetes.
Erectile Dysfunction
PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction.
Erectile Dysfunction
PDE-5 inhibitors in selected herbal supplements from the Ghanaian market for better erectile function as tested by a bioassay.
Erectile Dysfunction
PDE-5 Inhibitors: Clinical Points.
Erectile Dysfunction
PDE-5 inhibitors: current status and future trends.
Erectile Dysfunction
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
Erectile Dysfunction
PDE5 inhibitors beyond erectile dysfunction.
Erectile Dysfunction
PDE5 inhibitors for LUTS.
Erectile Dysfunction
PDE5 inhibitors in non-urological conditions.
Erectile Dysfunction
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Erectile Dysfunction
Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy.
Erectile Dysfunction
Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking?
Erectile Dysfunction
Penile Rehabilitation: The "Up"-date.
Erectile Dysfunction
Perceptions of Erectile Dysfunction and Phosphodiesterase Type 5 Inhibitor Therapy in a Qualitative Study of Men and Women in Affected Relationships.
Erectile Dysfunction
Pericyte-Derived Dickkopf2 Regenerates Damaged Penile Neurovasculature Through an Angiopoietin-1-Tie2 Pathway.
Erectile Dysfunction
Perspectives on urological care in multiple sclerosis patients.
Erectile Dysfunction
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Pharmacogenetics of erectile dysfunction: navigating into uncharted waters.
Erectile Dysfunction
Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions.
Erectile Dysfunction
Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors.
Erectile Dysfunction
Pharmacokinetics and bioequivalence of sildenafil granules and sildenafil tablets in Korean healthy volunteers.
Erectile Dysfunction
Pharmacokinetics of a New Orodispersible Tablet Formulation of Vardenafil: Results of Three Clinical Trials.
Erectile Dysfunction
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Erectile Dysfunction
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Erectile Dysfunction
Pharmacologic treatment for pulmonary arterial hypertension.
Erectile Dysfunction
Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression.
Erectile Dysfunction
Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Erectile Dysfunction
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
Erectile Dysfunction
Pharmacological treatment for premature ejaculation.
Erectile Dysfunction
Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Erectile Dysfunction
Pharmacology of phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Pharmacotherapy for erectile dysfunction.
Erectile Dysfunction
Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Erectile Dysfunction
Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.
Erectile Dysfunction
Phase I and registry study of autologous bone marrow concentrate evaluated in PDE5 inhibitor refractory erectile dysfunction.
Erectile Dysfunction
Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors.
Erectile Dysfunction
Phenolic analysis and erectogenic function of African Walnut (Tetracarpidium conophorum) seeds: The impact of the seed shell on biological activity.
Erectile Dysfunction
Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products.
Erectile Dysfunction
Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
Erectile Dysfunction
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Erectile Dysfunction
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Erectile Dysfunction
Phosphodiesterase 5 inhibition: effects on the coronary vasculature.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Erectile Dysfunction
Phosphodiesterase 5 Inhibitors from Derris scandens.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles.
Erectile Dysfunction
Phosphodiesterase 5 inhibitors: current status and potential applications.
Erectile Dysfunction
Phosphodiesterase inhibitors and the eye.
Erectile Dysfunction
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Erectile Dysfunction
Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
Erectile Dysfunction
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Erectile Dysfunction
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.
Erectile Dysfunction
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase type 5 in men with vasculogenic and post-radical prostatectomy erectile dysfunction: is there a molecular difference?
Erectile Dysfunction
Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors and Female Sexual Response: Faulty Protocols or Paradigms?
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors and kidney disease.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
Erectile Dysfunction
Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
Erectile Dysfunction
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Erectile Dysfunction
Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Erectile Dysfunction
Phosphodiesterase type-5 inhibitors for erectile dysfunction following nerve-sparing radical prostatectomy: A network meta-analysis.
Erectile Dysfunction
Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.
Erectile Dysfunction
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Erectile Dysfunction
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Erectile Dysfunction
Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Erectile Dysfunction
Phosphodiesterase-5 Inhibitors Could Be Efficacious in the Treatment of Erectile Dysfunction after Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Erectile Dysfunction
Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Erectile Dysfunction
Phosphodiesterase-5 inhibitors: future perspectives.
Erectile Dysfunction
Phosphodiesterase-5 inhibitors: Shedding new light on the darkness of depression?
Erectile Dysfunction
Phosphodiesterases 5 inhibitors and erectile dysfunction recovery after pelvic surgery: future perspectives for new drugs and new formulations.
Erectile Dysfunction
Pituitary adenoma apoplexy associated with vardenafil intake.
Erectile Dysfunction
Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
Erectile Dysfunction
Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study.
Erectile Dysfunction
Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
Erectile Dysfunction
Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
Erectile Dysfunction
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
Erectile Dysfunction
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Erectile Dysfunction
Preconditioning of adipose-derived stem cells by phosphodiesterase-5 inhibition enhances therapeutic efficacy against diabetes-induced erectile dysfunction.
Erectile Dysfunction
Predictors of response to sildenafil citrate following radiation therapy for prostate cancer.
Erectile Dysfunction
Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
Erectile Dysfunction
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency.
Erectile Dysfunction
Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats.
Erectile Dysfunction
Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study.
Erectile Dysfunction
Prevalence of erectile dysfunction oral drugs use in a city of southern Brazil.
Erectile Dysfunction
Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrergic and pro-oxidant mechanisms.
Erectile Dysfunction
Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Erectile Dysfunction
Pulmonary embolism after tadalafil ingestion.
Erectile Dysfunction
Randomised Trial of CPAP and Vardenafil on Erectile and Arterial Function in Men with Obstructive Sleep Apnea and Erectile Dysfunction.
Erectile Dysfunction
Rapid detection and identification of counterfeit of adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
Erectile Dysfunction
Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements.
Erectile Dysfunction
Re: A Cost-Utility Analysis of Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction.
Erectile Dysfunction
Re: comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Erectile Dysfunction
Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
Erectile Dysfunction
Re: Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Erectile Dysfunction
Re: JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
Erectile Dysfunction
Re: Panagiotis Kallidonis, Constantinos Adamou, Dimitrios Kotsiris, et al. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:537-58.
Erectile Dysfunction
Re: Placebo Responses among Men with Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-Analysis.
Erectile Dysfunction
Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
Re: zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Real-World Assessment of the Impact of Erectile Dysfunction on Sexual Planning Behavior and Health- and Treatment-Related Outcomes Among Men in 8 Countries.
Erectile Dysfunction
Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.
Erectile Dysfunction
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students.
Erectile Dysfunction
Recurrent uveitis due to sildenafil usage in a patient with Behçet's disease.
Erectile Dysfunction
Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction.
Erectile Dysfunction
Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke.
Erectile Dysfunction
Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil.
Erectile Dysfunction
Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.
Erectile Dysfunction
Relaxation of rabbit corpus cavernosum smooth muscle and aortic vascular endothelium induced by new nitric oxide donor substances of the nitrosyl-ruthenium complex.
Erectile Dysfunction
Reno-protective effects of Phosphodiesterase 5 inhibitors.
Erectile Dysfunction
Renoprotective Effects of Sildenafil in DOCA-Salt Hypertensive Rats.
Erectile Dysfunction
Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'.
Erectile Dysfunction
Reply to Francesco Montorsi, Eugenio Ventimiglia, and Andrea Salonia's Letter to the Editor re: Panagiotis Kallidonis, Constantinos Adamou, Dimitrios Kotsiris, et al. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:537-58.
Erectile Dysfunction
Reply to Letter to the Editor: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors.
Erectile Dysfunction
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
Erectile Dysfunction
Research in pharmacotherapy for erectile dysfunction.
Erectile Dysfunction
Restoration of satisfying sex for a castrated cancer patient with complete impotence: a case study.
Erectile Dysfunction
Resveratrol Stimulates Hydrogen Sulfide (H2 S) Formation to Relax Murine Corpus Cavernosum.
Erectile Dysfunction
Reversible bilateral subfoveal ellipsoid zone focal thickening associated with overdose of phosphodiesterase type 5 inhibitors intake.
Erectile Dysfunction
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Erectile Dysfunction
Rewarding properties of sildenafil citrate in mice: role of the nitric oxide-cyclic GMP pathway.
Erectile Dysfunction
Risk of erectile dysfunction associated with use of 5-? reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Erectile Dysfunction
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Erectile Dysfunction
Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Erectile Dysfunction
Robot-assisted radical prostatectomy in the setting of previous abdominal surgery: Perioperative results, oncological and functional outcomes, and complications in a single surgeon's series.
Erectile Dysfunction
Robotic radical prostatectomy in 93 cases: Outcomes of the first ERUS robotic urology curriculum trained surgeon in Turkey.
Erectile Dysfunction
Role of Hydrogen Sulfide in the Physiology of Penile Erection.
Erectile Dysfunction
Role of sildenafil in neurological disorders.
Erectile Dysfunction
Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction.
Erectile Dysfunction
Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan.
Erectile Dysfunction
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
Erectile Dysfunction
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial.
Erectile Dysfunction
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine.
Erectile Dysfunction
Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.
Erectile Dysfunction
Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism.
Erectile Dysfunction
Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: preliminary report.
Erectile Dysfunction
Scaffoldless tissue engineering of stem cell derived cavernous tissue for treatment of erectile function.
Erectile Dysfunction
Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: Analytical techniques and challenges.
Erectile Dysfunction
Screening sexual performance enhancing compounds and their analogues in counterfeit and illicit erectile dysfunction drugs by high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry.
Erectile Dysfunction
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.
Erectile Dysfunction
Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Erectile Dysfunction
Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability.
Erectile Dysfunction
Separate or Combined Treatments with Daily Sildenafil, Molsidomine, or Muscle-Derived Stem Cells Prevent Erectile Dysfunction in a Rat Model of Cavernosal Nerve Damage.
Erectile Dysfunction
Serum homocysteine levels and sildenafil 50 mg response in young-adult male patients without vascular risk factors.
Erectile Dysfunction
Sexual activity in normal married couples in Japan: Investigation by questionnaire.
Erectile Dysfunction
Sexual dysfunction after radical prostatectomy: treatment failure or treatment delay?
Erectile Dysfunction
Sexual dysfunction and infertility in the male spina bifida patient.
Erectile Dysfunction
Sexual dysfunction in medical practice.
Erectile Dysfunction
Sexual dysfunction in men with type 2 diabetes.
Erectile Dysfunction
Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: An Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire.
Erectile Dysfunction
Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men.
Erectile Dysfunction
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Should Low-intensity Extracorporeal Shockwave Therapy Be the First-line Erectile Dysfunction Treatment for Nonresponders to Phosphodiesterase Type 5 Inhibition?
Erectile Dysfunction
Side effects of using nitrates to treat angina.
Erectile Dysfunction
Sildenafil (Viagra) and ophthalmology.
Erectile Dysfunction
Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.
Erectile Dysfunction
Sildenafil (viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device.
Erectile Dysfunction
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Erectile Dysfunction
Sildenafil accelerates liver regeneration after partial hepatectomy in rats.
Erectile Dysfunction
Sildenafil Acutely Decreases Visual Responses in ON and OFF Retinal Ganglion Cells.
Erectile Dysfunction
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Erectile Dysfunction
Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity.
Erectile Dysfunction
Sildenafil augments fetal weight and placental adiponectin in gestational testosterone-induced glucose intolerant rats.
Erectile Dysfunction
Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.
Erectile Dysfunction
Sildenafil can induce the onset of a cluster headache bout.
Erectile Dysfunction
Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness.
Erectile Dysfunction
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Erectile Dysfunction
Sildenafil citrate does not affect cardiac contractility in human or dog heart.
Erectile Dysfunction
Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers.
Erectile Dysfunction
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.
Erectile Dysfunction
Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.
Erectile Dysfunction
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.
Erectile Dysfunction
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.
Erectile Dysfunction
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Erectile Dysfunction
Sildenafil in erectile dysfunction: a critical review.
Erectile Dysfunction
Sildenafil in ophthalmology: An update.
Erectile Dysfunction
Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide.
Erectile Dysfunction
Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
Erectile Dysfunction
Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
Erectile Dysfunction
Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial.
Erectile Dysfunction
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Erectile Dysfunction
Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.
Erectile Dysfunction
Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study.
Erectile Dysfunction
Sildenafil restores endothelial function in the apolipoprotein E knockout mouse.
Erectile Dysfunction
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Erectile Dysfunction
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Erectile Dysfunction
Sildenafil's impact on male infertility: what has changed in 20 years?
Erectile Dysfunction
Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro.
Erectile Dysfunction
Sildenafil-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Case report with review.
Erectile Dysfunction
Sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of the heat shock-related protein 20 (HSP20).
Erectile Dysfunction
Sildenafil: efficacy and safety in daily clinical experience.
Erectile Dysfunction
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Erectile Dysfunction
Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men.
Erectile Dysfunction
Sonography of the penis/erectile dysfunction.
Erectile Dysfunction
Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor.
Erectile Dysfunction
Spotlight on vardenafil in erectile dysfunction.
Erectile Dysfunction
Structural characterization of sulfoaildenafil, an analog of sildenafil.
Erectile Dysfunction
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Erectile Dysfunction
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Erectile Dysfunction
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
Erectile Dysfunction
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Erectile Dysfunction
Sudden sensorineural hearing loss associated with vardenafil.
Erectile Dysfunction
Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes.
Erectile Dysfunction
Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial.
Erectile Dysfunction
Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
Erectile Dysfunction
Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
Erectile Dysfunction
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Erectile Dysfunction
Synergistic Effects of BAY 60-4552 and Vardenafil on Relaxation of Corpus Cavernosum Tissue of Patients with Erectile Dysfunction and Clinical Phosphodiesterase Type 5 Inhibitor Failure.
Erectile Dysfunction
Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.
Erectile Dysfunction
Synthesis and Structure Revision of Dimeric Tadalafil Analogue Adulterants in Dietary Supplements.
Erectile Dysfunction
Systematic Review and Meta-Analysis of the Use of Phosphodiesterase Type 5 Inhibitors for Treatment of Erectile Dysfunction following Bilateral Nerve-Sparing Radical Prostatectomy.
Erectile Dysfunction
Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Erectile Dysfunction
Systemic and metabolic effects of PDE5-inhibitor drugs.
Erectile Dysfunction
T-type (alpha1G) low voltage-activated calcium channel interactions with nitric oxide-cyclic guanosine monophosphate pathway and regulation of calcium homeostasis in human cavernosal cells.
Erectile Dysfunction
Tadalafil - a therapeutic option in the management of BPH-LUTS.
Erectile Dysfunction
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
Erectile Dysfunction
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Erectile Dysfunction
Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats.
Erectile Dysfunction
Tadalafil as an in vitro sperm motility stimulant.
Erectile Dysfunction
Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice.
Erectile Dysfunction
Tadalafil for benign prostatic hyperplasia.
Erectile Dysfunction
Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Erectile Dysfunction
Tadalafil for the treatment of pulmonary arterial hypertension.
Erectile Dysfunction
Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization.
Erectile Dysfunction
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Erectile Dysfunction
Tadalafil in the treatment of erectile dysfunction.
Erectile Dysfunction
Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-Induced Matrix Protein Synthesis in Podocytes.
Erectile Dysfunction
Tadalafil Lilly ICOS.
Erectile Dysfunction
Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model.
Erectile Dysfunction
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Erectile Dysfunction
Tadalafil significantly reduces ischemia reperfusion injury in skin island flaps.
Erectile Dysfunction
Tadalafil therapy for erectile dysfunction following prostatectomy.
Erectile Dysfunction
Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.
Erectile Dysfunction
Tadalafil-loaded nanostructured lipid carriers using permeation enhancers.
Erectile Dysfunction
Tadalafil.
Erectile Dysfunction
Tadalafil: a new agent for erectile dysfunction.
Erectile Dysfunction
Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia.
Erectile Dysfunction
Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.
Erectile Dysfunction
Ten Years of Phosphodiesterase Type 5 Inhibitors in Spinal Cord Injured Patients.
Erectile Dysfunction
Ten-Year Follow-Up of Sildenafil Use in Spinal Cord-Injured Patients with Erectile Dysfunction.
Erectile Dysfunction
TESTOSTERONE DEFICIT SYNDROME AND ERECTILE DYSFUNCTION.
Erectile Dysfunction
Testosterone Replacement Therapy: Should It Be Performed in Erectile Dysfunction?
Erectile Dysfunction
Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease.
Erectile Dysfunction
Testosterone therapy improves erectile function and libido in hypogonadal men.
Erectile Dysfunction
Testosterone therapy in erectile dysfunction and hypogonadism.
Erectile Dysfunction
Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.
Erectile Dysfunction
The application of color Doppler flow imaging in the diagnosis and therapeutic effect evaluation of erectile dysfunction.
Erectile Dysfunction
The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
Erectile Dysfunction
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Erectile Dysfunction
The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
Erectile Dysfunction
The cardiovascular safety of tadalafil.
Erectile Dysfunction
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Erectile Dysfunction
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.
Erectile Dysfunction
The daily intake of Tadalafil 5 mg improves the symptoms of chronic anal fissure.
Erectile Dysfunction
The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
Erectile Dysfunction
The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.
Erectile Dysfunction
The effect of antihypertensive drugs on erectile function: a proposed management algorithm.
Erectile Dysfunction
The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction.
Erectile Dysfunction
The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury.
Erectile Dysfunction
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.
Erectile Dysfunction
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial.
Erectile Dysfunction
The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.
Erectile Dysfunction
The effect of vardenafil on endothelial function of brachial and cavernous arteries.
Erectile Dysfunction
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
Erectile Dysfunction
The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
Erectile Dysfunction
The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism.
Erectile Dysfunction
The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
Erectile Dysfunction
The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.
Erectile Dysfunction
The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction.
Erectile Dysfunction
The efficacy and safety of tadalafil: an update.
Erectile Dysfunction
The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.
Erectile Dysfunction
The efficacy and safety of vardenafil in East Asian men with erectile dysfunction.
Erectile Dysfunction
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial.
Erectile Dysfunction
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Erectile Dysfunction
The HelpED Study: Agreement and Impact of the Erection Hardness Score on Sexual Function and Psychosocial Outcomes in Men with Erectile Dysfunction and Their Partners.
Erectile Dysfunction
The impact of sildenafil on molecular science and sexual health.
Erectile Dysfunction
The Management of Erectile Dysfunction with Placebo Only: Does it Work?
Erectile Dysfunction
The management of erectile dysfunction: innovations and future perspectives.
Erectile Dysfunction
The management of phosphodiesterase-5 (PDE5) inhibitor failure.
Erectile Dysfunction
The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Erectile Dysfunction
The Old Made New: Natural Compounds against Erectile Dysfunction.
Erectile Dysfunction
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Erectile Dysfunction
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Erectile Dysfunction
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
Erectile Dysfunction
The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?
Erectile Dysfunction
The relationship between erectile dysfunction and cardiovascular disease. Part I: pathophysiology and mechanisms.
Erectile Dysfunction
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Erectile Dysfunction
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors.
Erectile Dysfunction
The Role of Initial Success Rates and Other Factors in Determining Reliability of Outcomes of Phosphodiesterase Inhibitor Therapy for Erectile Dysfunction: A Pooled Analysis of 17 Placebo-Controlled Trials of Tadalafil for Use as Needed.
Erectile Dysfunction
The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
Erectile Dysfunction
The role of nitric oxide in erectile dysfunction: implications for medical therapy.
Erectile Dysfunction
The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
Erectile Dysfunction
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Erectile Dysfunction
The role of serum testosterone testing: routine hormone analysis is an essential part of the initial screening of men with erectile dysfunction.
Erectile Dysfunction
The role of statins in erectile dysfunction.
Erectile Dysfunction
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA.
Erectile Dysfunction
The start of pharmacological activity after sublingual administration of sildenafil citrate in 30 patients affected by erectile dysfunction.
Erectile Dysfunction
The therapeutic dilemma: how to use tadalafil.
Erectile Dysfunction
The use of phosphodiesterase 5 inhibitors with concomitant medications.
Erectile Dysfunction
The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Erectile Dysfunction
Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
Erectile Dysfunction
Thinking About Pathomechanisms and Current Treatment of Erectile Dysfunction-"The Stanley Beamish Problem." Review, Recommendations, and Proposals.
Erectile Dysfunction
Three important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathway.
Erectile Dysfunction
Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
Erectile Dysfunction
Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials.
Erectile Dysfunction
Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil.
Erectile Dysfunction
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Erectile Dysfunction
Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Erectile Dysfunction
Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy.
Erectile Dysfunction
Topically delivered nitric oxide acts synergistically with an orally administered PDE5 inhibitor in eliciting an erectile response in a rat model of radical prostatectomy.
Erectile Dysfunction
Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.
Erectile Dysfunction
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release.
Erectile Dysfunction
Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Erectile Dysfunction
Transient Rise of Serum Testosterone Level after Single Sildenafil Treatment of Adult Male Rats.
Erectile Dysfunction
Treating Erectile Dysfunction and Central Neurological Diseases with Oral Phosphodiesterase Type 5 Inhibitors. Review of the Literature.
Erectile Dysfunction
Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Erectile Dysfunction
Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
Erectile Dysfunction
Treatment of dysautonomia associated with Parkinson's disease.
Erectile Dysfunction
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Erectile Dysfunction
Treatment of infertility in men with spinal cord injury.
Erectile Dysfunction
Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
Erectile Dysfunction
Treatment Options for Urogenital Dysfunction in Parkinson's Disease.
Erectile Dysfunction
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
Erectile Dysfunction
Treatment Satisfaction of Men and Partners Following Switch from On-Demand Phosphodiesterase Type 5 Inhibitor Therapy to Tadalafil 5?mg Once Daily.
Erectile Dysfunction
Treatment Strategy for Non-Responders to PDE5 Inhibitors.
Erectile Dysfunction
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
Erectile Dysfunction
Treatments for erectile dysfunction in spinal cord lesioned patients. Are there alternatives to phosphodiesterase type 5 inhibitors?
Erectile Dysfunction
Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.
Erectile Dysfunction
Treatments for erectile dysfunction in spinal cord patients: Alternatives to phosphodiesterase type 5 inhibitors? A review study.
Erectile Dysfunction
Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors.
Erectile Dysfunction
Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease.
Erectile Dysfunction
Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
Erectile Dysfunction
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Erectile Dysfunction
Type 5 phosphodiesterase inhibitors: curing erectile dysfunction.
Erectile Dysfunction
UHPLC for quality evaluation of genuine and illegal medicines containing sildenafil citrate and tadalafil.
Erectile Dysfunction
Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction.
Erectile Dysfunction
Up-titration of vardena fi l dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury.
Erectile Dysfunction
Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Erectile Dysfunction
Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Erectile Dysfunction
Ups and downs of Viagra: revisiting ototoxicity in the mouse model.
Erectile Dysfunction
Urethral diverticulum after endoscopic urethrotomy: case report.
Erectile Dysfunction
Urinary and sexual manifestations of patients infected by HTLV-I.
Erectile Dysfunction
Urological aspects of HIV and AIDS.
Erectile Dysfunction
Urologist practice patterns in the management of premature ejaculation: a nationwide survey.
Erectile Dysfunction
Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples.
Erectile Dysfunction
Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy.
Erectile Dysfunction
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Erectile Dysfunction
Use of phosphodiesterase-5 inhibitors by college students.
Erectile Dysfunction
Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Erectile Dysfunction
Utilization and prescription patterns of phosphidiesterase-5 inhibitor medications in the United States military health system.
Erectile Dysfunction
Vacuum therapy in erectile dysfunction-science and clinical evidence.
Erectile Dysfunction
Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples.
Erectile Dysfunction
Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
Erectile Dysfunction
Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
Erectile Dysfunction
Vardenafil can Improve Continence Recovery after Bilateral Nerve Sparing Prostatectomy: Results of a Randomized, Double Blind, Placebo-Controlled Pilot Study.
Erectile Dysfunction
Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand.
Erectile Dysfunction
Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification.
Erectile Dysfunction
Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction.
Erectile Dysfunction
Vardenafil in men with stable statin therapy and dyslipidemia.
Erectile Dysfunction
Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
Erectile Dysfunction
Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG.
Erectile Dysfunction
Vardenafil restores erectile function to normal range in men with erectile dysfunction.
Erectile Dysfunction
Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study.
Erectile Dysfunction
Vardenafil.
Erectile Dysfunction
Vardenafil: a new approach to the treatment of erectile dysfunction.
Erectile Dysfunction
Vardenafil: a new oral treatment for erectile dysfunction.
Erectile Dysfunction
Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.
Erectile Dysfunction
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
Erectile Dysfunction
Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction.
Erectile Dysfunction
Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches.
Erectile Dysfunction
Versatile effects of sildenafil: recent pharmacological applications.
Erectile Dysfunction
Viagra (sildenafil citrate) and ophthalmology.
Erectile Dysfunction
Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database.
Erectile Dysfunction
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Erectile Dysfunction
Visual Side Effects Linked to Sildenafil Consumption: An Update.
Erectile Dysfunction
Words of wisdom. Re: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. Paick J-S, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh J-K, Kim SC.
Erectile Dysfunction
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
Erectile Dysfunction
[Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction]
Erectile Dysfunction
[AN EVIDENCE BASED UPDATE ON THE INVESTIGATION AND MANAGEMENT OF MALE LOWER URINARY TRACT SYMPTOMS].
Erectile Dysfunction
[Application of the vacuum erectile device in penile rehabilitation for erectile dysfunction after radical prostatectomy].
Erectile Dysfunction
[Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI].
Erectile Dysfunction
[Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption]
Erectile Dysfunction
[Chronic PDE-5 inhibition in patients with erectile dysfunction : New treatment approach using once daily Tadalafil.]
Erectile Dysfunction
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study].
Erectile Dysfunction
[Combination therapy in benign prostatic hyperplasia (BPH)]
Erectile Dysfunction
[Combined treatment of patients with erectile dysfunction and urination disorders].
Erectile Dysfunction
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction]
Erectile Dysfunction
[Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities].
Erectile Dysfunction
[Current role of sildenafil in the management of erectile dysfunction].
Erectile Dysfunction
[Dosage forms of sildenafil in the management of erectile dysfunction].
Erectile Dysfunction
[ED patients and their female partners prefer tadalafil].
Erectile Dysfunction
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
Erectile Dysfunction
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]
Erectile Dysfunction
[Efficacy and safety of vardenadil in difficult-to-treat erectile dysfunction men]
Erectile Dysfunction
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
Erectile Dysfunction
[Erectile dysfunction and incontinence after prostatectomy. Treating the complications of surgery for prostate cancer].
Erectile Dysfunction
[Erectile dysfunction and phosphodiesterase type 5 inhibitors]
Erectile Dysfunction
[Evaluation of tadalafil for the treatment of erectile dysfunction]
Erectile Dysfunction
[Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction]
Erectile Dysfunction
[Features of subjects purchasing Sildenafil at community pharmacies in Concepción, Chile]
Erectile Dysfunction
[Good sex inspite of erectile dysfunction. A new PDE-5 inhibitor gives more latitude]
Erectile Dysfunction
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Erectile Dysfunction
[Hydrogen sulfide and penile erection].
Erectile Dysfunction
[Identification of Descarbonsildenafil in an Adulterated Dietary Supplement and Evaluation of Its Inhibitory Activity for Phosphodiesterase Type 5 (PDE5)].
Erectile Dysfunction
[Impact of rAd5-shRNA- PDE5A3 on cGMP in the smooth muscle cells of human corpus cavernosum]
Erectile Dysfunction
[Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]
Erectile Dysfunction
[Levitra (wardenafil) effects on endothelial function of brachial and cavernous arteries]
Erectile Dysfunction
[Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update].
Erectile Dysfunction
[Low-dose tadalafil improves arterial erectile dysfunction]
Erectile Dysfunction
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Erectile Dysfunction
[Medicinal therapy of benign prostate syndrome].
Erectile Dysfunction
[Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of oral dispersible tablet].
Erectile Dysfunction
[New application of phosphodiesterase-5 inhibitors in uro-andrology].
Erectile Dysfunction
[New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
Erectile Dysfunction
[New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again]
Erectile Dysfunction
[New treatment strategies for male lower urinary tract symptoms].
Erectile Dysfunction
[Patient with testosterone deficit syndrome and erectile dysfunction non-responder to PDE-5 inhibitors].
Erectile Dysfunction
[PDE5 inhibitors as a medicinal guide drug in the treatment of erectile dysfunction].
Erectile Dysfunction
[PDE5 inhibitors for the management of temporary penile erectile dysfunction during treatment with assisted reproductive technology].
Erectile Dysfunction
[Pharmacological treatment of benign prostatic hyperplasia].
Erectile Dysfunction
[Pharmacological treatment of BPS].
Erectile Dysfunction
[Phosphodiesterase 5 inhibition in erectile dysfunction. Long-term administration without therapeutic advantage]
Erectile Dysfunction
[Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]
Erectile Dysfunction
[Phosphodiesterase inhibitors in clinical practice. The present and the future. Part I]
Erectile Dysfunction
[Phosphodiesterase inhibitors: effectiveness and new applications]
Erectile Dysfunction
[Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies].
Erectile Dysfunction
[Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Erectile Dysfunction
[Phosphodiesterase type 5 siRNA increases cGMP in the smooth muscle cells of human corpus cavernosum]
Erectile Dysfunction
[Phosphodiesterase-5 inhibitors for erectile dysfunction: Adverse reactions and countermeasures].
Erectile Dysfunction
[Safety of tadalafil in patients with cardiovascular comorbidities].
Erectile Dysfunction
[Sexual activity and cardiovascular risk]
Erectile Dysfunction
[Sexuality in the elderly : The role of the physicians in maintaining sexual health of older men].
Erectile Dysfunction
[Should we recommend an erectile rehabilitation after radical prostatectomy? Systematic review of the literature by the Sexual Medicine Committee of the French Urology Association].
Erectile Dysfunction
[Sildenafil assumption and acute effects on the uroflowmetric parameters.]
Erectile Dysfunction
[Sildenafil]
Erectile Dysfunction
[Single base polymorphisms and erectile dysfunction.]
Erectile Dysfunction
[Tadalafil for erectile dysfunction: efficacy evaluation]
Erectile Dysfunction
[Tadalafil for erectile dysfunction: excellent safety and tolerance]
Erectile Dysfunction
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]
Erectile Dysfunction
[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Erectile Dysfunction
[The effects of sildenafil citrate on the isolated rat aorta: comparative in vitro study]
Erectile Dysfunction
[The treatments of localized prostate cancer: the impact on sexuality]
Erectile Dysfunction
[Therapeutic effect of phosphodiesterase-5 inhibitor on pathological changes of tunica albuginea in erectile dysfunction: experiment with rats]
Erectile Dysfunction
[Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction]
Erectile Dysfunction
[Therapy for organic erectile dysfunction]
Erectile Dysfunction
[Therapy of erectile dysfunction. New, highly selective PDE-5 inhibitor]
Erectile Dysfunction
[Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)]
Erectile Dysfunction
[TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING TRANSVESICAL PROSTATECTOMY].
Erectile Dysfunction
[Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three]
Erectile Dysfunction
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Erectile Dysfunction
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]
Erectile Dysfunction
[Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
Erectile Dysfunction
[Urinary and sexual disorders following localised prostate cancer management].
Erectile Dysfunction
[Viagra, cialis, impase--which of them, to whom, when and how?]
Erectile Dysfunction
[Whole rehabilitation: a new goal of erectile dysfunction therapy]
Escherichia coli Infections
Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection.
Esophageal Achalasia
Effect of sildenafil, a phosphodiesterase-5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function in cats.
Esophageal Achalasia
Treatment of esophageal motility disorders based on the chicago classification.
Essential Hypertension
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Essential Hypertension
Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension.
Essential Hypertension
ERECTILE DYSFUNCTION AS A PREDICTOR OF CARDIOVASCULAR DISEASE.
Essential Hypertension
Phosphodiesterase 5 inhibition in essential hypertension.
Essential Hypertension
Phosphodiesterase 5 inhibition to treat essential hypertension: is this the beginning of the story?
Eye Diseases
Generalized progressive retinal atrophy of Sloughi dogs is due to an 8-bp insertion in exon 21 of the PDE6B gene.
Eye Diseases
Retinal imaging in inherited retinal diseases.
Familial Primary Pulmonary Hypertension
Conservative management of an elderly patient with Eisenmenger syndrome.
Familial Primary Pulmonary Hypertension
Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
Familial Primary Pulmonary Hypertension
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement.
Familial Primary Pulmonary Hypertension
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Familial Primary Pulmonary Hypertension
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Familial Primary Pulmonary Hypertension
Hepatopulmonary syndrome and portopulmonary hypertension: what's new?
Familial Primary Pulmonary Hypertension
Iloprost for idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Familial Primary Pulmonary Hypertension
Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets.
Familial Primary Pulmonary Hypertension
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease.
Familial Primary Pulmonary Hypertension
Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
Familial Primary Pulmonary Hypertension
Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Familial Primary Pulmonary Hypertension
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
Familial Primary Pulmonary Hypertension
The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial.
Familial Primary Pulmonary Hypertension
Treatment of primary pulmonary hypertension with oral sildenafil.
Familial Primary Pulmonary Hypertension
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
Familial Primary Pulmonary Hypertension
[Cardio-vascular effects of sildenafil: new data]
Familial Primary Pulmonary Hypertension
[Treatment of pulmonary hypertension]
Fetal Growth Retardation
Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report.
Fetal Growth Retardation
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Fetal Growth Retardation
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Fetal Growth Retardation
Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice.
Fetal Growth Retardation
The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus.
Fetal Growth Retardation
The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Fetal Hypoxia
Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial.
Fissure in Ano
Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone.
Gastroesophageal Reflux
Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology.
Glaucoma
Identification of PDE6D as a Molecular Target of Anecortave Acetate via a Methotrexate-Anchored Yeast Three-Hybrid Screen.
Glaucoma
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Glaucoma
Urologic medications and ophthalmologic side effects: a review.
Glioblastoma
Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.
Glioblastoma
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Glioma
Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.
Glomerulonephritis
PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.
Glomerulonephritis
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Glomerulonephritis, IGA
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Glucose Metabolism Disorders
Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue.
Gyrate Atrophy
Retinal imaging in inherited retinal diseases.
Head and Neck Neoplasms
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
Hearing Loss
A Natural Occurring Mouse Model with Adgrv1 Mutation of Usher Syndrome 2C and Characterization of its Recombinant Inbred Strains.
Hearing Loss
Comprehensive Molecular Screening in Chinese Usher Syndrome Patients.
Hearing Loss
Drug-induced hearing loss.
Hearing Loss
Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil.
Hearing Loss
Histopathologic results of long-term sildenafil administration on rat inner ear.
Hearing Loss
Phosphodiesterase type 5 inhibitor use and hearing impairment.
Hearing Loss
Sudden sensorineural hearing loss associated with vardenafil.
Hearing Loss
Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors.
Hearing Loss, Noise-Induced
Therapeutic effect of sildenafil on blast-induced tinnitus and auditory impairment.
Hearing Loss, Sensorineural
Phosphodiesterase type 5 inhibitors and sudden sensorineural hearing loss.
Hearing Loss, Sensorineural
Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
Hearing Loss, Sensorineural
Sudden hearing loss after cialis (tadalafil) use: A unique case of cochlear hydrops.
Hearing Loss, Sensorineural
Sudden sensorineural hearing loss associated with vardenafil.
Hearing Loss, Sudden
Effect of phosphodiesterase-5 inhibitor on hearing.
Hearing Loss, Sudden
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Heart Arrest
Sildenafil after cardiac arrest and infarction; an experimental rat model.
Heart Arrest
The protective effects of phosphodiesterase-5 inhibitor, sildenafil on post-resuscitation cardiac dysfunction of cardiac arrest: by regulating the miR-155-5p and miR-145-5p.
Heart Arrest
The protective effects of phosphodiesterase-5 inhibitor, sildenafil on post-resuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis.
Heart Defects, Congenital
Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
Heart Defects, Congenital
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Heart Diseases
An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
Heart Diseases
Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.
Heart Diseases
Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Heart Diseases
Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study.
Heart Diseases
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Heart Diseases
Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
Heart Diseases
Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
Heart Diseases
Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients.
Heart Diseases
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Heart Diseases
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
Heart Diseases
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Heart Diseases
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
Heart Failure
Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure.
Heart Failure
An MRTF-A-Sp1-PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy.
Heart Failure
Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.
Heart Failure
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Heart Failure
Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.
Heart Failure
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Heart Failure
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Heart Failure
Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Heart Failure
Chronic Inhibition of Cyclic Guanosine Monophosphate-Specific Phosphodiesterase 5 Suppresses Endoplasmic Reticulum Stress in Heart Failure.
Heart Failure
Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction.
Heart Failure
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Heart Failure
Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure.
Heart Failure
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems.
Heart Failure
Differential effects of phosphodiesterase-5 inhibition in chronic cardiac decompensation, depending on the type, whether HFREF or HFpEF, of heart failure: a meta-analysis.
Heart Failure
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Heart Failure
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Heart Failure
Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
Heart Failure
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Heart Failure
Endothelin-1 and peak oxygen consumption in patients with heart failure with preserved ejection fraction.
Heart Failure
Enhancement of Myocardial and Vascular Function after Phosphodiesterase-5 Inhibition in a Rat Model.
Heart Failure
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Heart Failure
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Heart Failure
Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Heart Failure
Improved erectile function after cardiac resynchronization therapy in a patient with heart failure-a case report.
Heart Failure
Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.
Heart Failure
Letter by Cingolani et al regarding article, "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice".
Heart Failure
Letter by forfia and borlaug regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Heart Failure
Letter by gordon et Al regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Heart Failure
Letter by Hutchings et al Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation : An INTERMACS Analysis".
Heart Failure
Letter by jamous regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Heart Failure
Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
Heart Failure
Long-term use of sildenafil in the therapeutic management of heart failure.
Heart Failure
MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.
Heart Failure
Mitigation of the Progression of Heart Failure with Sildenafil Involves Inhibition of RhoA/Rho-Kinase Pathway.
Heart Failure
Non erectile dysfunction application of sildenafil.
Heart Failure
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
Heart Failure
Oral sildenafil: Potential role in heart transplantation. Review of the literature and personal experience.
Heart Failure
Oxidative stress regulates left ventricular PDE5 expression in the failing heart.
Heart Failure
PDE5 inhibitor efficacy is estrogen dependent in female heart disease.
Heart Failure
Phosphodiesterase 5 Associates With ?2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
Heart Failure
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Heart Failure
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Heart Failure
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.
Heart Failure
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G I? Oxidation.
Heart Failure
Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
Heart Failure
Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
Heart Failure
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Heart Failure
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Heart Failure
Phosphodiesterase 9 Inhibition in Models of Heart Failure With Preserved Left Ventricular Ejection Fraction: Should We Focus on the Positive or Negative?
Heart Failure
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
Heart Failure
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Heart Failure
Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
Heart Failure
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
Heart Failure
Phosphodiesterase-5 inhibitors: future perspectives.
Heart Failure
Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
Heart Failure
Phosphodiesterases and cardiac cGMP: evolving roles and controversies.
Heart Failure
Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
Heart Failure
Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.
Heart Failure
Prevention of Right Heart Failure After Left Ventricular Assist Device Implantation by Phosphodiesterase 5 Inhibitor.
Heart Failure
Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Heart Failure
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Heart Failure
Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Heart Failure
Response by Blanton et al to Letter Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After LVAD Implantation: An INTERMACS Analysis".
Heart Failure
RETRACTION NOTE TO: Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Heart Failure
Right heart failure after left ventricular assist device implantation: early and late.
Heart Failure
Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.
Heart Failure
S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation.
Heart Failure
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Heart Failure
Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model.
Heart Failure
Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
Heart Failure
Sildenafil and Cardioprotection.
Heart Failure
Sildenafil and phosphodiesterase-5 inhibitors for heart failure.
Heart Failure
Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs.
Heart Failure
Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Heart Failure
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Heart Failure
Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
Heart Failure
Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil.
Heart Failure
T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters.
Heart Failure
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
Heart Failure
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
Heart Failure
The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure.
Heart Failure
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study.
Heart Failure
The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
Heart Failure
The emerging role for type 5 phosphodiesterase inhibitionin heart failure.
Heart Failure
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Heart Failure
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Heart Failure
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Heart Failure
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Heart Failure
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Heart Failure
Type 5 phosphodiesterase inhibition in heart failure: the next step.
Heart Failure
Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil.
Heart Failure
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
Heart Failure
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Heart Failure
[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].
Heart Failure, Diastolic
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction.
Heart Failure, Diastolic
Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial.
Heart Failure, Diastolic
Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Heart Failure, Diastolic
Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
Heart Failure, Diastolic
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
Heart Failure, Systolic
Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
Heart Failure, Systolic
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Heart Failure, Systolic
Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.
Heart Rupture
Phosphodiesterase-5a Knock-out Suppresses Inflammation by Down-Regulating Adhesion Molecules in Cardiac Rupture Following Myocardial Infarction.
Heart Valve Diseases
Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
Hemangioma
Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.
Hematologic Diseases
Independent Predictive Factors for Occurrence of Ischemic Priapism after Papaverine Injection.
Hernias, Diaphragmatic, Congenital
Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.
Hernias, Diaphragmatic, Congenital
Dypiridamole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia.
HIV Infections
High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.
HIV Seropositivity
The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention.
Hodgkin Disease
Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin's disease lymphocytes.
Hodgkin Disease
t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.
Huntington Disease
Chromosome mapping of the rod photoreceptor cGMP phosphodiesterase beta-subunit gene in mouse and human: tight linkage to the Huntington disease region (4p16.3).
Huntington Disease
Exclusion of DNA changes in the beta-subunit of the c-GMP phosphodiesterase gene as the cause for Huntington's disease.
Huntington Disease
Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p 16.3.
Huntington Disease
Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF.
Hyperalgesia
Characterization of a novel model of chronic migraine.
Hyperalgesia
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
Hyperalgesia
NO/cGMP production is important for the endogenous peripheral control of hyperalgesia during inflammation.
Hyperalgesia
Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil.
Hyperalgesia
The kappa-opioid agonist (+/-)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway.
Hypercholesterolemia
The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Hyperemia
Phosphodiesterase-5 Inhibitor Use: An Under-reported Cause of Profuse Nasal Bleeding.
Hyperemia
Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.
Hyperglycemia
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Hyperglycemia
Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats.
Hyperglycemia
Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.
Hyperglycemia
Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia: no effect of phosphodiesterase-5 (PDE-5) inhibition.
Hyperhomocysteinemia
Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia.
Hyperlipidemias
Mechanisms underlying dysfunction of carotid arteries in genetically hyperlipidemic rabbits.
Hyperlipoproteinemia Type II
Differential impact of severe familial hypercholesterolemia on regional skeletal muscle and organ blood flows during exercise: Effects of PDE5 inhibition.
Hypersensitivity
Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
Hypertension
3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Hypertension
A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
Hypertension
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
Hypertension
A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.
Hypertension
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Hypertension
A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.
Hypertension
Abnormalities of platelet function in hypertension and diabetes.
Hypertension
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Hypertension
Acute, Bilateral, Concurrent Central Retinal Artery Occlusion in Sickle Cell Disease After Use of Tadalafil (Cialis).
Hypertension
Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Hypertension
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Hypertension
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Hypertension
An evidence-based approach to the management of pulmonary arterial hypertension.
Hypertension
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Hypertension
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Hypertension
Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension.
Hypertension
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Hypertension
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Hypertension
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Hypertension
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Hypertension
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Hypertension
Classical activation of macrophages and vardenafil.
Hypertension
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
Hypertension
Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension.
Hypertension
Clinical use of sildenafil in pulmonary artery hypertension.
Hypertension
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Hypertension
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Hypertension
Comparison of health-related quality-of-life outcomes for African-American and Caucasian-American men after radical prostatectomy.
Hypertension
Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.
Hypertension
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.
Hypertension
Conservative management of an elderly patient with Eisenmenger syndrome.
Hypertension
Conversion From Sildenafil to Tadalafil: Results From the Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) Study.
Hypertension
Current diagnosis and management of erectile dysfunction.
Hypertension
Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension.
Hypertension
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
Hypertension
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Hypertension
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Hypertension
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Hypertension
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Hypertension
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Hypertension
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Hypertension
Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
Hypertension
Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
Hypertension
Effect of regular phosphodiesterase type 5 inhibition in hypertension.
Hypertension
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Hypertension
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Hypertension
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Hypertension
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Hypertension
Effect of treating erectile dysfunction on management of systolic hypertension.
Hypertension
Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Hypertension
Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.
Hypertension
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Hypertension
Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy.
Hypertension
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
Hypertension
Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
Hypertension
Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog.
Hypertension
Emerging therapies for the treatment of pulmonary hypertension.
Hypertension
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Hypertension
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Hypertension
Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.
Hypertension
Erectile dysfunction and hypertension.
Hypertension
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Hypertension
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Hypertension
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Hypertension
Extracts from Almond (Terminalia catappa) leaf and stem bark mitigate the activities of crucial enzymes and oxidative stress associated with hypertension in cyclosporine A-stressed rats.
Hypertension
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
Hypertension
Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.
Hypertension
Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan.
Hypertension
Future treatments in systemic sclerosis.
Hypertension
Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment.
Hypertension
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
Hypertension
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies.
Hypertension
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
Hypertension
Iloprost for idiopathic pulmonary arterial hypertension.
Hypertension
Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
Hypertension
In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5.
Hypertension
In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil.
Hypertension
Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.
Hypertension
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Hypertension
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
Hypertension
Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.
Hypertension
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Hypertension
Letter by forfia and borlaug regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Hypertension
Letter by gordon et Al regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Hypertension
Letter by jamous regarding article, "pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".
Hypertension
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Hypertension
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Hypertension
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Hypertension
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
Hypertension
Medical treatment update on pulmonary arterial hypertension.
Hypertension
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
Hypertension
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Hypertension
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.
Hypertension
New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?
Hypertension
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.
Hypertension
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Hypertension
Nonaneurysmal Subarachnoid Hemorrhage after Udenafil Intake.
Hypertension
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
Hypertension
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
Hypertension
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Hypertension
One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease.
Hypertension
Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension.
Hypertension
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Hypertension
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial.
Hypertension
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial.
Hypertension
PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
Hypertension
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Hypertension
Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report.
Hypertension
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Hypertension
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Hypertension
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Hypertension
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Hypertension
Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction.
Hypertension
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Hypertension
Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.
Hypertension
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Hypertension
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Hypertension
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Hypertension
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Hypertension
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Hypertension
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Hypertension
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Hypertension
Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia.
Hypertension
Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
Hypertension
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Hypertension
Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
Hypertension
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Hypertension
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Hypertension
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study.
Hypertension
Portopulmonary hypertension and right heart failure in patients with cirrhosis.
Hypertension
Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease.
Hypertension
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Hypertension
Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency.
Hypertension
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Hypertension
Pulmonary arterial hypertension.
Hypertension
Pulmonary Hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach.
Hypertension
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Hypertension
Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets.
Hypertension
Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
Hypertension
Pulmonary hypertension in systemic lupus erythematosus.
Hypertension
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Hypertension
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hypertension
Recent advances in the treatment of systemic sclerosis.
Hypertension
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
Hypertension
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
Hypertension
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hypertension
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Hypertension
Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children.
Hypertension
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
Hypertension
RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.
Hypertension
Right ventricular failure: a novel era of targeted therapy.
Hypertension
Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.
Hypertension
Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.
Hypertension
Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Hypertension
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
Hypertension
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.
Hypertension
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Hypertension
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Hypertension
Selexipag: A Review in Pulmonary Arterial Hypertension.
Hypertension
Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Hypertension
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Hypertension
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Hypertension
Sildenafil for pulmonary arterial hypertension.
Hypertension
Sildenafil for Pulmonary Arterial Hypertension.
Hypertension
Sildenafil for pulmonary arterial hypertension: when blue turns into white.
Hypertension
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Hypertension
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.
Hypertension
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Hypertension
Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.
Hypertension
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Hypertension
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Hypertension
Sildenafil: a review of its use in pulmonary arterial hypertension.
Hypertension
Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
Hypertension
Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension.
Hypertension
Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.
Hypertension
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Hypertension
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Hypertension
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Hypertension
Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology.
Hypertension
Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
Hypertension
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hypertension
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Hypertension
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Hypertension
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hypertension
Tadalafil for benign prostatic hyperplasia.
Hypertension
Tadalafil for the treatment of pulmonary arterial hypertension.
Hypertension
Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
Hypertension
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Hypertension
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Hypertension
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
Hypertension
Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.
Hypertension
Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Hypertension
Tadalafil: in pulmonary arterial hypertension.
Hypertension
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
Hypertension
The hypertensive effect of sorafenib is abolished by sildenafil.
Hypertension
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
Hypertension
The molecular targets of approved treatments for pulmonary arterial hypertension.
Hypertension
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Hypertension
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Hypertension
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Hypertension
The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells.
Hypertension
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Hypertension
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Hypertension
Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations.
Hypertension
Treatment Algorithms for Systemic Sclerosis According to Experts.
Hypertension
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Hypertension
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Hypertension
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
Hypertension
ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Hypertension
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
Hypertension
Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.
Hypertension
Vacuum Erection Devices Revisited: Its Emerging Role in the Treatment of Erectile Dysfunction and Early Penile Rehabilitation Following Prostate Cancer Therapy.
Hypertension
Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy.
Hypertension
Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.
Hypertension
Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
Hypertension
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Hypertension
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
Hypertension
[Correlation between hypertension and erectile dysfunction].
Hypertension
[Diagnosis and treatment of pulmonary hypertension].
Hypertension
[Drug-induced sexual dysfunction].
Hypertension
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
Hypertension
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.]
Hypertension
[Future aspects of the treatment of pulmonary arterial hypertension.]
Hypertension
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension]
Hypertension
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]
Hypertension
[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Hypertension
[Pulmonary arterial hypertension]
Hypertension
[The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease]
Hypertension
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]
Hypertension, Portal
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Hypertension, Portal
Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension.
Hypertension, Portal
Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Hypertension, Portal
Haemodynamic and renal effects of tadalafil in patients with cirrhosis.
Hypertension, Portal
Hepatopulmonary syndrome and portopulmonary hypertension: what's new?
Hypertension, Portal
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Hypertension, Portal
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pulmonary
A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine.
Hypertension, Pulmonary
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology.
Hypertension, Pulmonary
A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors.
Hypertension, Pulmonary
Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats.
Hypertension, Pulmonary
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Hypertension, Pulmonary
Acute pulmonary hypertension in infants and children: cGMP-related drugs.
Hypertension, Pulmonary
Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension.
Hypertension, Pulmonary
Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
Hypertension, Pulmonary
Additive Effect of Tadalafil and Simvastatin on monocrotaline-induced pulmonary hypertension rats.
Hypertension, Pulmonary
An Accidental Repetitive 10-Fold Overdose of Sildenafil in a Young Infant with Pulmonary Hypertension.
Hypertension, Pulmonary
An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension.
Hypertension, Pulmonary
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
Hypertension, Pulmonary
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Hypertension, Pulmonary
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Hypertension, Pulmonary
Cardioprotection with sildenafil: implications for clinical practice.
Hypertension, Pulmonary
Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Hypertension, Pulmonary
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
Hypertension, Pulmonary
Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion.
Hypertension, Pulmonary
Clinical trials in group 3 pulmonary hypertension.
Hypertension, Pulmonary
Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.
Hypertension, Pulmonary
Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
Hypertension, Pulmonary
Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs.
Hypertension, Pulmonary
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Hypertension, Pulmonary
Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses.
Hypertension, Pulmonary
Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons.
Hypertension, Pulmonary
Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals.
Hypertension, Pulmonary
DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
Hypertension, Pulmonary
DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats.
Hypertension, Pulmonary
Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood.
Hypertension, Pulmonary
Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.
Hypertension, Pulmonary
Differential expression of PDE5 in failing and nonfailing human myocardium.
Hypertension, Pulmonary
Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure.
Hypertension, Pulmonary
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Hypertension, Pulmonary
Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets.
Hypertension, Pulmonary
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
Hypertension, Pulmonary
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction.
Hypertension, Pulmonary
Effect of a Phosphodiesterase 5 Inhibitor on Pulmonary and Cerebral Arteries of Newborn Piglets with Chronic Hypoxia-Induced Pulmonary Hypertension.
Hypertension, Pulmonary
Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension.
Hypertension, Pulmonary
Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery.
Hypertension, Pulmonary
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Hypertension, Pulmonary
Effects and mechanisms of action of sildenafil citrate in human chorionic arteries.
Hypertension, Pulmonary
Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome.
Hypertension, Pulmonary
Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats.
Hypertension, Pulmonary
Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.
Hypertension, Pulmonary
Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos.
Hypertension, Pulmonary
Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5.
Hypertension, Pulmonary
Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Hypertension, Pulmonary
Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.
Hypertension, Pulmonary
Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice.
Hypertension, Pulmonary
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Hypertension, Pulmonary
Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with COPD and Pulmonary Hypertension.
Hypertension, Pulmonary
Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn.
Hypertension, Pulmonary
Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Hypertension, Pulmonary
Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide.
Hypertension, Pulmonary
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Hypertension, Pulmonary
Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
Hypertension, Pulmonary
Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Hypertension, Pulmonary
Inhibition of cGMP phosphodiesterase 5 suppresses MMP2 production in pulmonary artery smooth muscles cells.
Hypertension, Pulmonary
Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells.
Hypertension, Pulmonary
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling.
Hypertension, Pulmonary
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Hypertension, Pulmonary
Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
Hypertension, Pulmonary
Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome.
Hypertension, Pulmonary
Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
Hypertension, Pulmonary
Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension.
Hypertension, Pulmonary
L-Arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Hypertension, Pulmonary
Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.
Hypertension, Pulmonary
Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension.
Hypertension, Pulmonary
Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.
Hypertension, Pulmonary
Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
Hypertension, Pulmonary
Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Hypertension, Pulmonary
Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
Hypertension, Pulmonary
Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications.
Hypertension, Pulmonary
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
Hypertension, Pulmonary
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Hypertension, Pulmonary
Nebulized solid lipid nanoparticles for the potential treatment of pulmonary hypertension via targeted delivery of phosphodiesterase-5-inhibitor.
Hypertension, Pulmonary
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.
Hypertension, Pulmonary
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis.
Hypertension, Pulmonary
Ocular findings of oral sildenafil use in term and near-term neonates.
Hypertension, Pulmonary
Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation.
Hypertension, Pulmonary
Oxytocinergic system mediates the proconvulsant effects of sildenafil: The role of calcineurin.
Hypertension, Pulmonary
PDE-5 inhibitors: current status and future trends.
Hypertension, Pulmonary
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Hypertension, Pulmonary
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
Hypertension, Pulmonary
PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.
Hypertension, Pulmonary
Persistent pulmonary hypertension in the newborn: therapeutic effect of sildenafil.
Hypertension, Pulmonary
Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors.
Hypertension, Pulmonary
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Hypertension, Pulmonary
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Hypertension, Pulmonary
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Hypertension, Pulmonary
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Hypertension, Pulmonary
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Hypertension, Pulmonary
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibitors and kidney disease.
Hypertension, Pulmonary
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis.
Hypertension, Pulmonary
Phosphodiesterase type 5 inhibitors in pulmonary hypertension: a Hobson's choice for Indian patients.
Hypertension, Pulmonary
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
Hypertension, Pulmonary
Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia.
Hypertension, Pulmonary
Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis.
Hypertension, Pulmonary
Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
Hypertension, Pulmonary
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.
Hypertension, Pulmonary
Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period.
Hypertension, Pulmonary
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Hypertension, Pulmonary
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Hypertension, Pulmonary
Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrergic and pro-oxidant mechanisms.
Hypertension, Pulmonary
Pulmonary arterial hypertension and statins: an update.
Hypertension, Pulmonary
Pulmonary hypertension complicating congenital heart disease.
Hypertension, Pulmonary
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Hypertension, Pulmonary
Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors.
Hypertension, Pulmonary
Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Hypertension, Pulmonary
Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors.
Hypertension, Pulmonary
Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus.
Hypertension, Pulmonary
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Hypertension, Pulmonary
Recent advances in sarcoidosis.
Hypertension, Pulmonary
Reno-protective effects of Phosphodiesterase 5 inhibitors.
Hypertension, Pulmonary
Reversal of pulmonary arterial hypertension in POEMS syndrome with thalidomide: a case report.
Hypertension, Pulmonary
Right heart failure after left ventricular assist device implantation: early and late.
Hypertension, Pulmonary
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Hypertension, Pulmonary
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Hypertension, Pulmonary
Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Hypertension, Pulmonary
Selective pulmonary vasodilation induced by aerosolized zaprinast.
Hypertension, Pulmonary
Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil.
Hypertension, Pulmonary
sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.
Hypertension, Pulmonary
Sildenafil Acutely Decreases Visual Responses in ON and OFF Retinal Ganglion Cells.
Hypertension, Pulmonary
Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
Hypertension, Pulmonary
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Hypertension, Pulmonary
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Hypertension, Pulmonary
Sildenafil citrate monohydrate-cyclodextrin nanosuspension complexes for use in metered-dose inhalers.
Hypertension, Pulmonary
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Hypertension, Pulmonary
Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery.
Hypertension, Pulmonary
Sildenafil for the treatment of pulmonary hypertension in pediatric patients.
Hypertension, Pulmonary
Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension.
Hypertension, Pulmonary
Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
Hypertension, Pulmonary
Sildenafil in a cigarette smoke-induced model of COPD in the guinea-pig.
Hypertension, Pulmonary
Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.
Hypertension, Pulmonary
Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling.
Hypertension, Pulmonary
Sildenafil in the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Hypertension, Pulmonary
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Hypertension, Pulmonary
Simvastatin and sildenafil combine to attenuate pulmonary hypertension.
Hypertension, Pulmonary
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Hypertension, Pulmonary
Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.
Hypertension, Pulmonary
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Hypertension, Pulmonary
Sudden sensorineural hearing loss associated with vardenafil.
Hypertension, Pulmonary
SUPEROXIDE DISMUTASE AND INHALED NITRIC OXIDE NORMALIZE PHOSPHODIESTERASE 5 EXPRESSION AND ACTIVITY IN NEONATAL LAMBS WITH PERSISTENT PULMONARY HYPERTENSION.
Hypertension, Pulmonary
Supporting the use of sildenafil infusions in paediatric and neonatal intensive care - A compatibility study.
Hypertension, Pulmonary
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Hypertension, Pulmonary
Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension.
Hypertension, Pulmonary
Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation.
Hypertension, Pulmonary
Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.
Hypertension, Pulmonary
Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
Hypertension, Pulmonary
Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.
Hypertension, Pulmonary
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review.
Hypertension, Pulmonary
The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation.
Hypertension, Pulmonary
The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Hypertension, Pulmonary
The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
Hypertension, Pulmonary
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.
Hypertension, Pulmonary
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case-control study.
Hypertension, Pulmonary
The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis.
Hypertension, Pulmonary
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Hypertension, Pulmonary
The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Hypertension, Pulmonary
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.
Hypertension, Pulmonary
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Hypertension, Pulmonary
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
Hypertension, Pulmonary
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Hypertension, Pulmonary
Therapeutic options for digital ulcers in patients with systemic sclerosis.
Hypertension, Pulmonary
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Hypertension, Pulmonary
Treatment Algorithms in Systemic Lupus Erythematosus.
Hypertension, Pulmonary
Treatment of schistosomiasis-associated pulmonary hypertension.
Hypertension, Pulmonary
Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Hypertension, Pulmonary
Type II Diabetes Patients under Sildenafil Citrate: Case Series Showing Benefits and a Side Effect.
Hypertension, Pulmonary
Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Hypertension, Pulmonary
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Hypertension, Pulmonary
Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
Hypertension, Pulmonary
X-linked CD40 ligand deficiency in a 1-year-old male Shih Tzu with secondary Pneumocystis pneumonia.
Hypertension, Pulmonary
Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone.
Hypertension, Pulmonary
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
Hypertension, Pulmonary
[E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats]
Hypertension, Pulmonary
[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
Hypertension, Pulmonary
[Medical treatment of pulmonary arterial hypertension.]
Hypertension, Pulmonary
[Mountain sickness].
Hypertension, Pulmonary
[New treatments of pediatric pulmonary hypertension].
Hypertension, Pulmonary
[Recommended guideline for the use of medical therapy in pulmonary hypertension]
Hypertension, Pulmonary
[Sildenafil in the treatment of pulmonary hypertension]
Hypertension, Pulmonary
[Sildenafil reduces pressure and pulmonary resistance and increases susceptibility of pulmonary arteries to nitric oxide in primary pulmonary arterial hypertension]
Hypertension, Pulmonary
[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension].
Hypertension, Pulmonary
[Treatment algorithm for pulmonary arterial hypertension.]
Hypertension, Pulmonary
[Treatment of pulmonary hypertension associated with connective tissue disease]
Hypertension, Renal
Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Hypertension, Renovascular
Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension.
Hypertension, Renovascular
Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
Hypertension, Renovascular
Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension.
Hyperthyroidism
Changes of calmodulin concentration and cyclic 3',5'-nucleotide phosphodiesterase activities in cardiac muscle of hyper- and hypothyroid rats.
Hyperthyroidism
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Hyperthyroidism
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Hypertrophy, Right Ventricular
DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
Hypertrophy, Right Ventricular
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Hypertrophy, Right Ventricular
The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Hypertrophy, Right Ventricular
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
Hypogonadism
Aging and sexual health: getting to the problem.
Hypogonadism
Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States.
Hypogonadism
Clinical efficiency of combination therapy using testosterone replacement therapy, phosphodiesterase 5 inhibitors and Kampo herbal medicine for eugonadal patients with late-onset hypogonadism syndrome.
Hypogonadism
Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis.
Hypogonadism
Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction.
Hypogonadism
Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism.
Hypogonadism
Erectile dysfunction in aging male.
Hypogonadism
Hypogonadism and erectile dysfunction as harbingers of systemic disease.
Hypogonadism
Testosterone and erectile dysfunction.
Hypogonadism
TESTOSTERONE DEFICIT SYNDROME AND ERECTILE DYSFUNCTION.
Hypogonadism
Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes.
Hypogonadism
The evolving role of testosterone in the treatment of erectile dysfunction.
Hypogonadism
[Sexuality in overweight and obesity].
Hypotension
An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
Hypotension
Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function.
Hypotension
Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.
Hypotension
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease.
Hypotension
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery.
Hypotension
Melanocortins in the treatment of male and female sexual dysfunction.
Hypotension
Oral sildenafil increases skin hyperaemia induced by iontophoresis of sodium nitroprusside in healthy volunteers.
Hypotension
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Hypotension
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
Hypotension
Sexual function in hypertensive patients receiving treatment.
Hypotension
Side effects of using nitrates to treat angina.
Hypotension
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Hypotension
Sildenafil Increases Sympathetically Mediated Vascular Tone in Humans.
Hypotension
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Hypotension
The hemodynamic interactions of combination therapy with ?-blockers and phosphodiesterase-5 inhibitors compared to monotherapy with ?-blockers: a systematic review and meta-analysis.
Hypotension
The Safety of Preoperative Vardenafil in Patients Undergoing Coronary Artery Bypass Graft Surgery.
Hypotension
[Cardiovascular disease and sexuality]
Hypotension, Orthostatic
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Hypotension, Orthostatic
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Hypotension, Orthostatic
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Hypothyroidism
Cyclic nucleotide phosphodiesterases, insulin and thyroid hormones.
Idiopathic Pulmonary Fibrosis
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
MiR-200a inversely correlates with Hedgehog and TGF-? canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.
Idiopathic Pulmonary Fibrosis
Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis.
Infections
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Infections
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Infections
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Infections
Enhanced recovery from respiratory infection following treatment with a PDE-5 inhibitor: a single case study.
Infections
Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection.
Infections
Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series).
Infections
Seminal vesicles of infertile patients with male accessory gland infection: ultrasound evaluation after prolonged treatment with tadalafil, a selective phosphodiesterase-5 inhibitor.
Infections
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Inferior Wall Myocardial Infarction
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Infertility
Sildenafil's impact on male infertility: what has changed in 20 years?
Infertility, Male
Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
Infertility, Male
Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis.
Inflammatory Bowel Diseases
Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress.
Insulin Resistance
Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice.
Insulin Resistance
Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.
Insulin Resistance
Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells.
Insulin Resistance
Interaction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolism.
Insulin Resistance
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Insulin Resistance
PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes.
Insulin Resistance
The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
Insulin Resistance
Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.
Insulin Resistance
Type II Diabetes Patients under Sildenafil Citrate: Case Series Showing Benefits and a Side Effect.
Insulinoma
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Intellectual Disability
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Ischemic Stroke
Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.
Ischemic Stroke
Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Ischemic Stroke
Sildenafil improves scotoma after posterior cerebral infarctions: a case report.
Kidney Diseases
Phosphodiesterase type 5 inhibitors and kidney disease.
Kidney Failure, Chronic
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Kidney Failure, Chronic
Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation.
Kidney Failure, Chronic
The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Leber Congenital Amaurosis
AIPL1, the protein that is defective in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP phosphodiesterase.
Leber Congenital Amaurosis
Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase.
Leber Congenital Amaurosis
Retinal imaging in inherited retinal diseases.
Leukemia
Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension.
Leukemia, Myeloid, Acute
Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis.
Liver Cirrhosis
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Liver Cirrhosis
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.
Liver Cirrhosis
Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat.
Liver Cirrhosis
Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis.
Liver Cirrhosis
Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study.
Liver Cirrhosis
Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Liver Cirrhosis
Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.
Liver Cirrhosis
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Cirrhosis
Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver Cirrhosis.
Liver Cirrhosis
The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats.
Liver Cirrhosis
Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Liver Cirrhosis, Biliary
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Cirrhosis, Experimental
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Liver Diseases
Anti-Inflammatory Effects of Vardenafil Against Cholestatic Liver Damage in Mice: a Mechanistic Study.
Liver Diseases
Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study.
Liver Diseases
Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.
Liver Failure
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Liver Neoplasms
In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis.
Liver Neoplasms
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
Long QT Syndrome
Phosphodiesterase 5: A Novel Therapeutic Target in Long QT Syndrome.
Lung Diseases
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Lung Diseases
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Lung Diseases, Interstitial
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Lung Injury
Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.
Lupus Nephritis
Treatment Algorithms in Systemic Lupus Erythematosus.
Lymphoma
Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.
Macular Degeneration
Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.
Macular Degeneration
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Macular Degeneration
Retinal imaging in inherited retinal diseases.
Macular Degeneration
Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial.
Macular Edema
Clinical and genetic investigations of three Moroccan families with retinitis pigmentosa phenotypes.
Malaria
PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum.
Malaria
Topological polar surface area: a useful descriptor in 2D-QSAR.
Meconium Aspiration Syndrome
Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.
Medulloblastoma
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.
Melanoma
Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Melanoma
Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Melanoma
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Melanoma
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Melanoma
Expression and role of phosphodiesterase 5 in human malignant melanoma cell line.
Melanoma
Hard times for oncogenic BRAF-expressing melanoma cells.
Melanoma
Involvement of cGMP in cellular melatonin responses.
Melanoma
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Melanoma
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
Melanoma
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.
Melanoma
Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
Melanoma
Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Melanoma
Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.
Melanoma
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Melanoma
Photoreceptor proteins as cancer-retina antigens.
Melanoma
Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
Melanoma
Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Melanoma
Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.
Melanoma
Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells.
Melanoma
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Melanoma
Role of rare germline copy number variation in melanoma-prone patients.
Melanoma
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.
Melanoma
Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study.
Melanoma
Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe).
Melanoma
Targeting invasive properties of melanoma cells.
Melanoma
Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.
Melanoma
Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Melanoma
Viagra releases the brakes on melanoma growth.
Melanoma
Visible light modulates the expression of cancer-retina antigens.
Melanoma
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Melanoma
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Memory Disorders
Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Memory Disorders
Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice.
Memory Disorders
Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 ? and pCREB expression.
Memory Disorders
Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Metabolic Syndrome
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Metabolic Syndrome
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors.
Metabolic Syndrome
Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Metabolic Syndrome
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
Metabolic Syndrome
Sildenafil citrate long-term treatment effects on cardiovascular reactivity in a SHR experimental model of metabolic syndrome.
Metabolic Syndrome
Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.
Metabolic Syndrome
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Migraine Disorders
Cerebral haemodynamic response or excitability is not affected by sildenafil.
Migraine Disorders
Characterization of a novel model of chronic migraine.
Migraine Disorders
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Migraine Disorders
Migraine can be induced by sildenafil without changes in middle cerebral artery diameter.
Migraine Disorders
Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.
Migraine Disorders
Phosphodiesterase-5 inhibitors and migraine.
Migraine Disorders
Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Migraine Disorders
Sildenafil can trigger cluster headaches.
Mitral Valve Stenosis
[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]
Mononeuropathies
Treatment Algorithms in Systemic Lupus Erythematosus.
Multiple Sclerosis
Drugs that Can Kill a Toddler with One Tablet or Teaspoonful: A 2018 Updated List.
Multiple Sclerosis
Efficacy and Safety of Tadalafil for Erectile Dysfunction in Patients with Multiple Sclerosis.
Multiple Sclerosis
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Multiple Sclerosis
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Muscle Spasticity
New therapies for non-cardiac chest pain.
Muscle Spasticity
Two Distinct Types of Hypercontractile Esophagus: Classic and Spastic Jackhammer.
Muscle Weakness
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Muscular Atrophy
Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Muscular Diseases
Bilateral Knee and Intermittent Elbow Pain in a Competitive Archer/Hunter: Phosphodiesterase-5-Inhibitor-Statin Interaction?
Muscular Diseases
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Muscular Dystrophies
Efficacy of Phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation and survival rate.
Muscular Dystrophies
Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.
Muscular Dystrophy, Duchenne
PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Sildenafil and Cardioprotection.
Muscular Dystrophy, Duchenne
Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.
Myalgia
A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia.
Myalgia
Rhabdomyolysis induced by rosuvastatin and sildenafil.
Mydriasis
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Myocardial Infarction
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Myocardial Infarction
Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
Myocardial Infarction
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.
Myocardial Infarction
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Myocardial Infarction
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Myocardial Infarction
Erectile dysfunction therapy in special populations and applications: coronary artery disease.
Myocardial Infarction
Identification of a Functional PDE5A Variant at the Chromosome 4q27 Coronary Artery Disease Locus in an Extended Myocardial Infarction Family.
Myocardial Infarction
Letter by Cingolani et al regarding article, "Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice".
Myocardial Infarction
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Myocardial Infarction
Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4.
Myocardial Infarction
Phosphodiesterase 5 inhibition- induced coronary vasodilation is reduced after myocardial infarction.
Myocardial Infarction
Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.
Myocardial Infarction
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Myocardial Infarction
Serum cyclic 3',5'-nucleotide phosphodiesterase activity in myocardial infarction.
Myocardial Infarction
Sexual dysfunction in medical practice.
Myocardial Infarction
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.
Myocardial Infarction
The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
Myocardial Infarction
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Myocardial Infarction
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
Myocardial Infarction
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.
Myocardial Infarction
[Adenoviral short hairpin RNA targeting phosphodiesterase 5 attenuates cardiac remodeling and cardiac dysfunction following myocardial infarction in mice].
Myocardial Ischemia
Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: possible role of cardiac cyclic nucleotides.
Myocardial Ischemia
Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation.
Myocardial Ischemia
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease.
Myocardial Ischemia
Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium.
Myocardial Ischemia
The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.
Neoplasm Metastasis
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Neoplasm Metastasis
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer.
Neoplasm Metastasis
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Neoplasm, Residual
Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.
Neoplasms
67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis.
Neoplasms
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ?-catenin transcriptional activity.
Neoplasms
Activation of protein kinase G Increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1.
Neoplasms
An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies.
Neoplasms
Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition.
Neoplasms
Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?
Neoplasms
cGMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Neoplasms
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Neoplasms
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Neoplasms
Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?
Neoplasms
Drug-induced hearing loss.
Neoplasms
Endothelial Actions of ANP Enhance Myocardial Inflammatory Infiltration in the Early Phase After Acute Infarction.
Neoplasms
Exisulind Cell Pathways.
Neoplasms
Hard times for oncogenic BRAF-expressing melanoma cells.
Neoplasms
Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses.
Neoplasms
Increased guanylate cyclase activity and guanosine 3',5'-monophosphate content in ethionine-induced hepatomas.
Neoplasms
Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468.
Neoplasms
Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Neoplasms
Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach.
Neoplasms
Modulators of arginine metabolism support cancer immunosurveillance.
Neoplasms
MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.
Neoplasms
Neratinib augments the lethality of [regorafenib?+?sildenafil].
Neoplasms
Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells.
Neoplasms
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
Neoplasms
PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.
Neoplasms
PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types.
Neoplasms
PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.
Neoplasms
Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-cancer Drugs by PDE5 Inhibitors in Lung Cancer Cells.
Neoplasms
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Neoplasms
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.
Neoplasms
Phosphodiesterase type 5 and cancers: progress and challenges.
Neoplasms
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Neoplasms
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia.
Neoplasms
Psychological Impacts of Male Sexual Dysfunction in Pelvic Cancer Survivorship.
Neoplasms
Recovery of Baseline Erectile Function in Men Following Radical Prostatectomy for High-Risk Prostate Cancer: A Prospective Analysis Using Validated Measures.
Neoplasms
Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling.
Neoplasms
Retinoblastoma. A clinical, immunohistochemical, and electron microscopic case report.
Neoplasms
Roles of sildenafil in enhancing drug sensitivity in cancer.
Neoplasms
Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Neoplasms
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Neoplasms
Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide.
Neoplasms
Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.
Neoplasms
Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-?Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Neoplasms
Sulindac and its derivatives: a novel class of anticancer agents.
Neoplasms
Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/?-Catenin Signaling.
Neoplasms
Suppression of Cavernosal Fibrosis in a Rat Model.
Neoplasms
Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells.
Neoplasms
Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.
Neoplasms
Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective.
Neoplasms
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Neoplasms
Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1.
Neoplasms
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Neoplasms
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.
Neoplasms
The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
Neoplasms
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
Neoplasms
Topological polar surface area: a useful descriptor in 2D-QSAR.
Neoplasms
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Neoplasms
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Neoplasms
[Recurrence-free survival after radical prostatectomy and PDE-5 inhibitor intake].
Nephrotic Syndrome
Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat.
Nervous System Diseases
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.
Neuralgia
Effect of sildenafil on neuropathic pain and hemodynamics in rats.
Neuralgia
Phoshphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Neuralgia
The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.
Neuroblastoma
Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
Neuroblastoma
Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A.
Neurodegenerative Diseases
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Neurodegenerative Diseases
Role of sildenafil in neurological disorders.
Neuroinflammatory Diseases
Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice.
Neuroinflammatory Diseases
Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Neuroinflammatory Diseases
Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5.
Night Blindness
A truncated form of rod photoreceptor PDE6 ?-subunit causes autosomal dominant congenital stationary night blindness by interfering with the inhibitory activity of the ?-subunit.
Night Blindness
Gene for autosomal dominant congenital stationary night blindness maps to the same region as the gene for the beta-subunit of the rod photoreceptor cGMP phosphodiesterase (PDEB) in chromosome 4p16.3.
Night Blindness
Heterozygous missense mutation in the rod cGMP phosphodiesterase beta-subunit gene in autosomal dominant stationary night blindness.
Night Blindness
Identification and functional characterization of a novel rhodopsin mutation associated with autosomal dominant CSNB.
Night Blindness
Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B.
Night Blindness
Missense mutation in the gene encoding the alpha subunit of rod transducin in the Nougaret form of congenital stationary night blindness.
Night Blindness
Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture.
Night Blindness
Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit.
Night Blindness
Retinal imaging in inherited retinal diseases.
Night Blindness
Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma.
Night Blindness
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Obesity
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Obesity
Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic Peptide associated with obesity and hyperleptinemia.
Obesity
Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding.
Ocular Hypertension
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Optic Nerve Diseases
Acute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart disease.
Optic Nerve Diseases
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Optic Nerve Diseases
Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors.
Optic Nerve Diseases
Nonarteritic anterior ischaemic optic neuropathy.
Optic Nerve Diseases
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Optic Nerve Diseases
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Optic Nerve Diseases
Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.
Optic Nerve Diseases
Post-Marketing Surveillance of Ischaemic Optic Neuropathy in Male Veterans Co-Prescribed Phosphodiesterase-5 Inhibitors with Organic Nitrates or alpha-Blockers.
Optic Nerve Diseases
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis.
Optic Nerve Diseases
Toxic optic neuropathies: an updated review.
Optic Neuropathy, Ischemic
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Optic Neuropathy, Ischemic
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Optic Neuropathy, Ischemic
Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy.
Optic Neuropathy, Ischemic
Cases of Ischemic Optic Neuropathy Associated With Phosphodiesterase-5 Inhibitor Use Reported to the Food and Drug Administration Adverse Event Reporting System.
Optic Neuropathy, Ischemic
Drug-induced ocular disorders.
Optic Neuropathy, Ischemic
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Optic Neuropathy, Ischemic
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Optic Neuropathy, Ischemic
Literature commentary.
Optic Neuropathy, Ischemic
Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Optic Neuropathy, Ischemic
Non-arteritic anterior ischemic optic neuropathy, PDE-5 inhibitors, and amiodarone: may there be a sex hormone effect for the eye?
Optic Neuropathy, Ischemic
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Optic Neuropathy, Ischemic
Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?
Optic Neuropathy, Ischemic
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?
Optic Neuropathy, Ischemic
Prospective Case-Crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 Inhibitor (PDE5i) Exposure.
Optic Neuropathy, Ischemic
Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Optic Neuropathy, Ischemic
Sequential, non-arteritic anterior ischemic optic neuropathy in patients taking sildenafil: a report of ten cases.
Optic Neuropathy, Ischemic
Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.
Optic Neuropathy, Ischemic
The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
Optic Neuropathy, Ischemic
The Relationship Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.
Optic Neuropathy, Ischemic
Urologic medications and ophthalmologic side effects: a review.
Optic Neuropathy, Ischemic
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Optic Neuropathy, Ischemic
[Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)]
Osteonecrosis
Phosphodiesterase-5 inhibition improves bone regeneration at the early stages of ischemic osteonecrosis of the femoral head in rats.
Osteoporosis
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis.
Osteoporosis
Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease.
Osteoporosis
The NO-cGMP-PKG pathway in skeletal remodeling.
Osteoporosis
[The pathology of ocular syndromes caused by toxicity]
Ototoxicity
Effect of phosphodiesterase-5 inhibitor on hearing.
Ototoxicity
Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review.
Ototoxicity
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Parkinson Disease
Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.
Parkinson Disease
Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
Penile Induration
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Penile Induration
Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
Penile Induration
Expression of myosin isoforms in the smooth muscle of human corpus cavernosum.
Penile Induration
Peyronie's disease: evolving surgical management and the role of phosphodiesterase 5 inhibitors.
Penile Induration
Peyronie's disease: new paradigm for the treatment of a unique cause of erectile dysfunction.
Penile Induration
Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
Penile Induration
Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
Penile Induration
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
Pericarditis
Treatment Algorithms in Systemic Lupus Erythematosus.
Peripheral Arterial Disease
Improvement in symptoms of peripheral arterial disease with sildenafil therapy.
Peripheral Nervous System Diseases
Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice.
Peripheral Nervous System Diseases
MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions.
Peripheral Nervous System Diseases
PDE5 inhibitors in diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.
Peripheral Nervous System Diseases
Sildenafil Ameliorates Long Term Peripheral Neuropathy in Type II Diabetic Mice.
Peripheral Nervous System Diseases
Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.
Peripheral Nervous System Diseases
The role of miR-146a in dorsal root ganglia neurons of experimental diabetic peripheral neuropathy.
Peripheral Vascular Diseases
Intracavernous delivery of Dickkopf3 gene or peptide rescues erectile function through enhanced cavernous angiogenesis in the diabetic mouse.
Peripheral Vascular Diseases
PDE5 inhibitors in diabetic peripheral neuropathy.
Peripheral Vascular Diseases
Recent advances in the treatment of systemic sclerosis.
Pheochromocytoma
Nerve growth factor increases the cyclic GMP level and activates the cyclic GMP phosphodiesterase in PC12 cells.
Photophobia
Drug-induced ocular disorders.
Photophobia
Occupancy of the chromophore binding site of opsin activates visual transduction in rod photoreceptors.
Photophobia
Purification and characterization of S-modulin, a calcium-dependent regulator on cGMP phosphodiesterase in frog rod photoreceptors.
Photophobia
Reversible bilateral subfoveal ellipsoid zone focal thickening associated with overdose of phosphodiesterase type 5 inhibitors intake.
Photophobia
[Effect of sildenafil citrate on the cortical visual responses]
Pneumonia
Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice.
Pneumonia
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Polydactyly
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Pre-Eclampsia
A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia.
Pre-Eclampsia
Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia.
Pre-Eclampsia
Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor.
Pre-Eclampsia
Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries.
Pre-Eclampsia
Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Pre-Eclampsia
Phosphodiesterase Inhibitor Effect on Small Artery Function in Preeclampsia.
Pre-Eclampsia
Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia.
Pre-Eclampsia
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Pre-Eclampsia
Phosphodiesterases and preeclampsia.
Pre-Eclampsia
Placental effects and transfer of sildenafil in healthy and preeclamptic conditions.
Pre-Eclampsia
Sildenafil attenuates placental ischemia-induced hypertension.
Pre-Eclampsia
Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt-Sensitive Rat.
Pre-Eclampsia
Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.
Pre-Eclampsia
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Pre-Eclampsia
Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice.
Pre-Eclampsia
The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Prediabetic State
Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction.
Premature Birth
Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Premature Ejaculation
A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation.
Premature Ejaculation
Advances in treating premature ejaculation.
Premature Ejaculation
Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation.
Premature Ejaculation
Comparative efficacy and safety of phosphodiesterase-5 inhibitors with selective serotonin reuptake inhibitors in men with premature ejaculation: A systematic review and Bayesian network meta-analysis.
Premature Ejaculation
Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.
Premature Ejaculation
Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
Premature Ejaculation
Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Premature Ejaculation
Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men receiving selective serotonin reuptake inhibitors therapy: a systematic review and meta-analysis.
Premature Ejaculation
Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses.
Premature Ejaculation
Efficacy of Phosphodiesterase-5 Inhibitor in Men With Premature Ejaculation: A New Systematic Review and Meta-analysis.
Premature Ejaculation
Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review.
Premature Ejaculation
Interventions to Treat Erectile Dysfunction and Premature Ejaculation: An Overview of Systematic Reviews.
Premature Ejaculation
Lidocaine/prilocaine spray for premature ejaculation.
Premature Ejaculation
Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Premature Ejaculation
Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression.
Premature Ejaculation
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation.
Premature Ejaculation
Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Premature Ejaculation
Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis.
Premature Ejaculation
Phosphodiesterase-5 Inhibitors for Premature Ejaculation: Systematic Review and Meta-Analysis of Placebo-Controlled Trials.
Premature Ejaculation
Re: Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study.
Premature Ejaculation
Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.
Premature Ejaculation
Sexual Performance Anxiety.
Premature Ejaculation
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.
Premature Ejaculation
The Comparison of Combination SSRI and PDE-5 Inhibitor Therapy to SSRI Monotherapy in Men with Premature Ejaculation.
Premature Ejaculation
The Controversial Role of Phosphodiesterase Type 5 Inhibitors in the Treatment of Premature Ejaculation.
Premature Ejaculation
The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.
Premature Ejaculation
[New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
Premature Ejaculation
[Reflexions on 50 Years of Sexual Medicine in Urology Focusing on Male Sexual Dysfunctions].
Premature Ejaculation
[Treatment of premature ejaculation].
Priapism
Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
Priapism
Beneficial effect of the nitric oxide donor compound 3-(1,3-dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment.
Priapism
Castration for Treating Recurrent Priapism: Can We Do Better?
Priapism
DAILY PHOSPHODIESTERASE TYPE-5 INHIBITOR THERAPY AS RESCUE FOR RECURRENT ISCHEMIC PRIAPISM AFTER FAILED ANDROGEN ABLATION: A CASE REPORT.
Priapism
Daily tadalafil for the chronic phase of stuttering priapism: a case report.
Priapism
Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.
Priapism
Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Priapism
Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
Priapism
Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape.
Priapism
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Priapism
New Insights into the Pathophysiology of Sickle Cell Disease-Associated Priapism.
Priapism
Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report.
Priapism
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism.
Priapism
Priapism and Sickle-Cell Anemia: Diagnosis and Nonsurgical Therapy.
Priapism
Priapism in an Infant With Sickle Cell Trait After Cardiac Transplant.
Priapism
Psychotropic-Induced Priapism in a Treatment-Refractory Patient: A Case Report.
Priapism
Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism.
Priapism
Sickle cell trait and priapism: a case report and review of the literature.
Priapism
Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress.
Priapism
Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
Priapism
Tissue expression, distribution, and regulation of PDE5.
Priapism
Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.
Priapism
Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Priapism
Words of wisdom. Re: feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Prostatic Hyperplasia
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Prostatic Hyperplasia
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Prostatic Hyperplasia
Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Prostatic Hyperplasia
Assessment of the effect of mirodenafil on the hemodynamics of healthy male korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Prostatic Hyperplasia
Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
Prostatic Hyperplasia
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
Prostatic Hyperplasia
Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary Tract.
Prostatic Hyperplasia
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
Prostatic Hyperplasia
Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Prostatic Hyperplasia
Comorbid LUTS and erectile dysfunction: optimizing their management.
Prostatic Hyperplasia
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Prostatic Hyperplasia
Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Comparison of the Effects of Tadalafil and ?1-Adrenoceptor Antagonists on Spontaneous Seminal Emission and Electrical Field Stimulation-Induced Seminal Vesicle Contraction in Rats.
Prostatic Hyperplasia
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Prostatic Hyperplasia
Effect of PDE-5 inhibitors on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Prostatic Hyperplasia
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US.
Prostatic Hyperplasia
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Prostatic Hyperplasia
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Prostatic Hyperplasia
Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Prostatic Hyperplasia
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies.
Prostatic Hyperplasia
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Prostatic Hyperplasia
Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.
Prostatic Hyperplasia
Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies.
Prostatic Hyperplasia
EFFICIENCY OF SILDANEFIL MONOTHERAPY IN BENIGN PROSTATIC HYPERPLASIA.
Prostatic Hyperplasia
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue.
Prostatic Hyperplasia
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Prostatic Hyperplasia
Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors.
Prostatic Hyperplasia
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Prostatic Hyperplasia
Lower Urinary Tract Symptoms: What's New in Medical Treatment?
Prostatic Hyperplasia
Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.
Prostatic Hyperplasia
Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Prostatic Hyperplasia
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors.
Prostatic Hyperplasia
Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.
Prostatic Hyperplasia
Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Prostatic Hyperplasia
Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
Prostatic Hyperplasia
Phosphodiesterase Type 5 Inhibition Reverts Prostate Fibroblast-To-Myofibroblast Trans-Differentiation.
Prostatic Hyperplasia
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.
Prostatic Hyperplasia
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.
Prostatic Hyperplasia
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Prostatic Hyperplasia
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Prostatic Hyperplasia
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Prostatic Hyperplasia
Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia.
Prostatic Hyperplasia
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Prostatic Hyperplasia
Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
Prostatic Hyperplasia
Re: A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
Prostatic Hyperplasia
Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Prostatic Hyperplasia
Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with ?-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
Prostatic Hyperplasia
Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: in vitro and in vivo study.
Prostatic Hyperplasia
Study of phosphodiesterase 5 inhibitors and ?-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Prostatic Hyperplasia
Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and ?-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Prostatic Hyperplasia
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Prostatic Hyperplasia
Tadalafil for benign prostatic hyperplasia.
Prostatic Hyperplasia
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.
Prostatic Hyperplasia
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
Prostatic Hyperplasia
Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.
Prostatic Hyperplasia
The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?
Prostatic Hyperplasia
The Efficacy of PDE5 Inhibitors Alone or in Combination with Alpha-Blockers for the Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Prostatic Hyperplasia
The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Prostatic Hyperplasia
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Prostatic Hyperplasia
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Prostatic Hyperplasia
The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Prostatic Hyperplasia
The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Prostatic Hyperplasia
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Prostatic Hyperplasia
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
Prostatic Hyperplasia
Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.
Prostatic Hyperplasia
Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia.
Prostatic Hyperplasia
Vardenafil Decreases Bladder Afferent Nerve Activity in Unanesthetized, Decerebrate, Spinal Cord-Injured Rats.
Prostatic Hyperplasia
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study].
Prostatic Hyperplasia
[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Prostatic Hyperplasia
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
Prostatic Hyperplasia
[Recent progress in basic research concerning the management of benign prostatic hyperplasia]
Prostatic Hyperplasia
[Safety of tadalafil in patients with cardiovascular comorbidities].
Prostatic Hyperplasia
[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Prostatic Neoplasms
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Prostatic Neoplasms
Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Prostatic Neoplasms
Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Prostatic Neoplasms
Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Prostatic Neoplasms
Dickkopf2 rescues erectile function by enhancing penile neurovascular regeneration in a mouse model of cavernous nerve injury.
Prostatic Neoplasms
Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Prostatic Neoplasms
Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
Prostatic Neoplasms
Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Prostatic Neoplasms
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Prostatic Neoplasms
Long-term potency after early use of a vacuum erection device following radical prostatectomy.
Prostatic Neoplasms
Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury.
Prostatic Neoplasms
Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
Prostatic Neoplasms
Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
Prostatic Neoplasms
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.
Prostatic Neoplasms
Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Prostatic Neoplasms
Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
Prostatic Neoplasms
Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling.
Prostatic Neoplasms
Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis.
Prostatic Neoplasms
Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line.
Prostatic Neoplasms
Phosphodiesterase-5 Inhibitors Could Be Efficacious in the Treatment of Erectile Dysfunction after Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Prostatic Neoplasms
Predictors of response to sildenafil citrate following radiation therapy for prostate cancer.
Prostatic Neoplasms
Primary Care of the Prostate Cancer Survivor.
Prostatic Neoplasms
Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.
Prostatic Neoplasms
Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial.
Prostatic Neoplasms
Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men.
Prostatic Neoplasms
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Prostatic Neoplasms
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy.
Prostatic Neoplasms
The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Prostatic Neoplasms
The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Prostatic Neoplasms
Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy.
Prostatic Neoplasms
Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
Utilization of Pharmacotherapy for Erectile Dysfunction Following Treatment for Prostate Cancer.
Prostatic Neoplasms
[Urinary and sexual disorders following localised prostate cancer management].
Prostatitis
A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.
Prostatitis
Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain.
Prostatitis
Comparison of tamsulosin vs tamsulosin/sildenafil effectiveness in the treatment of erectile dysfunction in patients affected by type III chronic prostatitis.
Prostatitis
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
Prostatitis
[Experimental rodent models of chronic prostatitis: effect of phosphodiesterase 5 inhibitor on chronic pelvic-pain-related behavior].
Prostatitis
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]
Proteinuria
Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy.
Proteinuria
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Pseudorabies
Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass.
Psoriasis
Cyclic GMP metabolism in psoriasis: increased activity of soluble epidermal cyclic GMP phosphodiesterase and its modulation by calcium.
Pulmonary Arterial Hypertension
3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
Pulmonary Arterial Hypertension
A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
Pulmonary Arterial Hypertension
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Pulmonary Arterial Hypertension
A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Pulmonary Arterial Hypertension
Acute, Bilateral, Concurrent Central Retinal Artery Occlusion in Sickle Cell Disease After Use of Tadalafil (Cialis).
Pulmonary Arterial Hypertension
Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Pulmonary Arterial Hypertension
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Pulmonary Arterial Hypertension
An evidence-based approach to the management of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.
Pulmonary Arterial Hypertension
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Pulmonary Arterial Hypertension
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).
Pulmonary Arterial Hypertension
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
Pulmonary Arterial Hypertension
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Pulmonary Arterial Hypertension
Classical activation of macrophages and vardenafil.
Pulmonary Arterial Hypertension
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
Pulmonary Arterial Hypertension
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Pulmonary Arterial Hypertension
Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Conversion From Sildenafil to Tadalafil: Results From the Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) Study.
Pulmonary Arterial Hypertension
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
Pulmonary Arterial Hypertension
Development and validation of a GC/MS method for the determination of tadalafil in whole blood.
Pulmonary Arterial Hypertension
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification.
Pulmonary Arterial Hypertension
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Pulmonary Arterial Hypertension
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Pulmonary Arterial Hypertension
Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.
Pulmonary Arterial Hypertension
Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats.
Pulmonary Arterial Hypertension
Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice.
Pulmonary Arterial Hypertension
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Pulmonary Arterial Hypertension
Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.
Pulmonary Arterial Hypertension
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Pulmonary Arterial Hypertension
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
Pulmonary Arterial Hypertension
Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog.
Pulmonary Arterial Hypertension
Emerging therapies for the treatment of pulmonary hypertension.
Pulmonary Arterial Hypertension
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy.
Pulmonary Arterial Hypertension
Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5).
Pulmonary Arterial Hypertension
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Pulmonary Arterial Hypertension
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Future treatments in systemic sclerosis.
Pulmonary Arterial Hypertension
Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment.
Pulmonary Arterial Hypertension
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.
Pulmonary Arterial Hypertension
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies.
Pulmonary Arterial Hypertension
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
Pulmonary Arterial Hypertension
Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.
Pulmonary Arterial Hypertension
In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil.
Pulmonary Arterial Hypertension
Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Pulmonary Arterial Hypertension
Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
Pulmonary Arterial Hypertension
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Pulmonary Arterial Hypertension
Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan.
Pulmonary Arterial Hypertension
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Pulmonary Arterial Hypertension
Mechanisms Involved in the Remyelinating Effect of Sildenafil.
Pulmonary Arterial Hypertension
Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
Pulmonary Arterial Hypertension
Medical treatment update on pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
Pulmonary Arterial Hypertension
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Pulmonary Arterial Hypertension
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.
Pulmonary Arterial Hypertension
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Pulmonary Arterial Hypertension
Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease.
Pulmonary Arterial Hypertension
Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Pulmonary Arterial Hypertension
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial.
Pulmonary Arterial Hypertension
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial.
Pulmonary Arterial Hypertension
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.
Pulmonary Arterial Hypertension
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Pulmonary Arterial Hypertension
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Pulmonary Arterial Hypertension
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Pulmonary Arterial Hypertension
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 and high altitude pulmonary hypertension.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
Pulmonary Arterial Hypertension
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
Pulmonary Arterial Hypertension
Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
Pulmonary Arterial Hypertension
Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
Pulmonary Arterial Hypertension
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Pulmonary Arterial Hypertension
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Pulmonary Arterial Hypertension
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study.
Pulmonary Arterial Hypertension
Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.
Pulmonary Arterial Hypertension
Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Pulmonary Hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach.
Pulmonary Arterial Hypertension
Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.
Pulmonary Arterial Hypertension
Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.
Pulmonary Arterial Hypertension
Pulmonary hypertension in systemic lupus erythematosus.
Pulmonary Arterial Hypertension
Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
Pulmonary Arterial Hypertension
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Pulmonary Arterial Hypertension
Recent advances in the treatment of systemic sclerosis.
Pulmonary Arterial Hypertension
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
Pulmonary Arterial Hypertension
Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
Pulmonary Arterial Hypertension
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Pulmonary Arterial Hypertension
Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition.
Pulmonary Arterial Hypertension
Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children.
Pulmonary Arterial Hypertension
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
Pulmonary Arterial Hypertension
Right ventricular failure: a novel era of targeted therapy.
Pulmonary Arterial Hypertension
Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.
Pulmonary Arterial Hypertension
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Selexipag: A Review in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
Pulmonary Arterial Hypertension
Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.
Pulmonary Arterial Hypertension
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Sildenafil for Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Sildenafil for pulmonary arterial hypertension: when blue turns into white.
Pulmonary Arterial Hypertension
Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
Pulmonary Arterial Hypertension
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Pulmonary Arterial Hypertension
Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Pulmonary Arterial Hypertension
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Pulmonary Arterial Hypertension
Sildenafil: a review of its use in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors.
Pulmonary Arterial Hypertension
Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Pulmonary Arterial Hypertension
Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report.
Pulmonary Arterial Hypertension
Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
Pulmonary Arterial Hypertension
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Pulmonary Arterial Hypertension
Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes.
Pulmonary Arterial Hypertension
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Pulmonary Arterial Hypertension
Tadalafil for benign prostatic hyperplasia.
Pulmonary Arterial Hypertension
Tadalafil for the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.
Pulmonary Arterial Hypertension
Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Tadalafil: in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
Pulmonary Arterial Hypertension
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
Pulmonary Arterial Hypertension
The molecular targets of approved treatments for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Pulmonary Arterial Hypertension
Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Pulmonary Arterial Hypertension
Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations.
Pulmonary Arterial Hypertension
Treatment Algorithms for Systemic Sclerosis According to Experts.
Pulmonary Arterial Hypertension
Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
Pulmonary Arterial Hypertension
Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.
Pulmonary Arterial Hypertension
ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Pulmonary Arterial Hypertension
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.
Pulmonary Arterial Hypertension
Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.
Pulmonary Arterial Hypertension
Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
Pulmonary Arterial Hypertension
[Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension.]
Pulmonary Arterial Hypertension
[Diagnosis and treatment of pulmonary hypertension].
Pulmonary Arterial Hypertension
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
Pulmonary Arterial Hypertension
[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.]
Pulmonary Arterial Hypertension
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Pulmonary Arterial Hypertension
[Pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]
Pulmonary Disease, Chronic Obstructive
Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with COPD and Pulmonary Hypertension.
Pulmonary Disease, Chronic Obstructive
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Pulmonary Disease, Chronic Obstructive
Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
Pulmonary Disease, Chronic Obstructive
Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial.
Pulmonary Disease, Chronic Obstructive
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils.
Pulmonary Disease, Chronic Obstructive
Udenafil Improves Exercise Capacity in Patients with Chronic Obstructive Pulmonary Disease: A Prospective Study.
Pulmonary Edema
Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.
Pulmonary Edema
Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).
Pulmonary Edema
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Pulmonary Embolism
Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism.
Pulmonary Embolism
Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism.
Pulmonary Fibrosis
Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor.
Pulmonary Fibrosis
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.
Pulmonary Heart Disease
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
Pulmonary Veno-Occlusive Disease
Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease.
Pyelonephritis
Preventive effect of phosphodiesterase 5 inhibitor Tadalafil on experimental post-pyelonephritic renal injury in rats.
Raynaud Disease
On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.
Raynaud Disease
PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials.
Raynaud Disease
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.
Raynaud Disease
Therapeutic options for digital ulcers in patients with systemic sclerosis.
Raynaud Disease
[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome]
Rectal Neoplasms
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial.
Renal Insufficiency
Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAy mice.
Renal Insufficiency, Chronic
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Renal Insufficiency, Chronic
Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease.
Renal Insufficiency, Chronic
The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Reperfusion Injury
Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury.
Reperfusion Injury
Effect of the Phosphodiesterase-5 Inhibitor Zaprinast on Ischemia-Reperfusion Injury in Rats.
Reperfusion Injury
Effects of Sildenafil and Tadalafil on Edema and Reactive Oxygen Species Production in an Experimental Model of Lung Ischemia-Reperfusion Injury.
Reperfusion Injury
ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.
Reperfusion Injury
Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate.
Reperfusion Injury
Neuroprotective effect of tadalafil, a PDE-5 inhibitor, and its modulation by L-NAME in mouse model of ischemia-reperfusion injury.
Reperfusion Injury
Phosphodiesterase-5 inhibitor and rat lung ischemia-reperfusion injury.
Reperfusion Injury
Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.
Reperfusion Injury
Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G.
Reperfusion Injury
Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3{beta}.
Reperfusion Injury
sGC-cGMP-PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury.
Reperfusion Injury
[Protective effect of tadalafil against ischemia-reperfusion injury in rats].
Respiratory Distress Syndrome
Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.
Respiratory Distress Syndrome
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies.
Respiratory Insufficiency
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Retinal Degeneration
(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one ameliorates retinal degeneration in Pde6b
Retinal Degeneration
A Natural Occurring Mouse Model with Adgrv1 Mutation of Usher Syndrome 2C and Characterization of its Recombinant Inbred Strains.
Retinal Degeneration
A Naturally-Derived Compound Schisandrin B Enhanced Light Sensation in the pde6c Zebrafish Model of Retinal Degeneration.
Retinal Degeneration
A simple polymerase chain reaction assay for genotyping the retinal degeneration mutation (Pdeb(rd1)) in FVB/N-derived transgenic mice.
Retinal Degeneration
Analysis and quantitation of mRNAs encoding the alpha- and beta-subunits of rod photoreceptor cGMP phosphodiesterase in neonatal retinal degeneration (rd) mouse retinas.
Retinal Degeneration
Analysis of PDE6D and PDE6G genes for generalised progressive retinal atrophy (gPRA) mutations in dogs.
Retinal Degeneration
Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa.
Retinal Degeneration
Atypical retinal degeneration 3 in mice is caused by defective PDE6B pre-mRNA splicing.
Retinal Degeneration
bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations.
Retinal Degeneration
Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
Retinal Degeneration
Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window.
Retinal Degeneration
Comprehensive Molecular Screening in Chinese Usher Syndrome Patients.
Retinal Degeneration
Cone neurite sprouting: an early onset abnormality of the cone photoreceptors in the retinal degeneration mouse.
Retinal Degeneration
Correction: A Naturally-Derived Compound Schisandrin B Enhanced Light Sensation in the pde6c Zebrafish Model of Retinal Degeneration.
Retinal Degeneration
Cyclic GMP phosphodiesterase activator: Involvement in a hereditary retinal degeneration.
Retinal Degeneration
Destructive Changes in the Neuronal Structure of the FVB/N Mouse Retina.
Retinal Degeneration
Divergent Effects of HSP70 Overexpression in Photoreceptors During Inherited Retinal Degeneration.
Retinal Degeneration
Dopamine receptor loss of function is not protective of rd1 rod photoreceptors in vivo.
Retinal Degeneration
Effects of the rd1 mutation and host strain on hippocampal learning in mice.
Retinal Degeneration
Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration.
Retinal Degeneration
Exchange of Cone for Rod Phosphodiesterase 6 Catalytic Subunits in Rod Photoreceptors Mimics in Part Features of Light Adaptation.
Retinal Degeneration
Expression profiling of the retina of pde6c, a zebrafish model of retinal degeneration.
Retinal Degeneration
Frequency of the codon 807 mutation in the cGMP phosphodiesterase beta-subunit gene in Irish setters and other dog breeds with hereditary retinal degeneration.
Retinal Degeneration
FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis.
Retinal Degeneration
Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179.
Retinal Degeneration
Genetic expression of cyclic GMP phosphodiesterase activity defines abnormal photoreceptor differentiation in neurological mutants of inherited retinal degeneration.
Retinal Degeneration
Genotype-phenotype correlation of mouse pde6b mutations.
Retinal Degeneration
Hippocampal synaptic plasticity in mice carrying the rd mutation in the gene encoding cGMP phosphodiesterase type 6 (PDE6).
Retinal Degeneration
Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse.
Retinal Degeneration
Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice.
Retinal Degeneration
Involvement of cyclic GMP phosphodiesterase activator in an hereditary retinal degeneration.
Retinal Degeneration
IQCB1 and PDE6B mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds.
Retinal Degeneration
Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase.
Retinal Degeneration
Long-term effects of human induced pluripotent stem cell-derived retinal cell transplantation in Pde6b knockout rats.
Retinal Degeneration
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa.
Retinal Degeneration
Molecular characterization and mapping of canine cGMP-phosphodiesterase delta subunit (PDE6D).
Retinal Degeneration
Neurotoxicity of cGMP in the vertebrate retina: from the initial research on rd mutant mice to zebrafish genetic approaches.
Retinal Degeneration
NIH Swiss and Black Swiss mice have retinal degeneration and performance deficits in cognitive tests.
Retinal Degeneration
Novel immunodeficient Pde6b rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration.
Retinal Degeneration
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy.
Retinal Degeneration
Re-evaluation casts doubt on the pathogenicity of homozygous USH2A p.C759F.
Retinal Degeneration
Reduced rhodopsin phosphorylation during retinal dystrophy.
Retinal Degeneration
Restoration of Vision in the pde6?-deficient Dog, a Large Animal Model of Rod-cone Dystrophy.
Retinal Degeneration
Retinal Degeneration and rd1 Mutation in NC/Tnd Mice-A Human Atopic Dermatitis Model.
Retinal Degeneration
Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase.
Retinal Degeneration
Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase.
Retinal Degeneration
Retinal degeneration is rescued in transgenic rd mice by expression of the cGMP phosphodiesterase beta subunit.
Retinal Degeneration
Retinitis pigmentosa and retinal degeneration in animals: a review.
Retinal Degeneration
Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse.
Retinal Degeneration
Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
Retinal Degeneration
RNA-Seq reveals differential expression profiles and functional annotation of genes involved in retinal degeneration in Pde6c mutant Danio rerio.
Retinal Degeneration
Screening of the gene encoding the alpha'-subunit of cone cGMP-PDE in patients with retinal degenerations.
Retinal Degeneration
Stationary night blindness or progressive retinal degeneration in mice carrying different alleles of PDE gamma.
Retinal Degeneration
The regulatory subunit of PDE6 interacts with PACSIN in photoreceptors.
Retinal Degeneration
Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.
Retinal Degeneration
Up-regulation of tumor necrosis factor superfamily genes in early phases of photoreceptor degeneration.
Retinal Degeneration
Variable phenotypic expressivity in inbred retinal degeneration mouse lines: A comparative study of C3H/HeOu and FVB/N rd1 mice.
Retinal Degeneration
[Early changes in retinal 5'-nucleotidase activity in hereditary retinal degeneration]
Retinal Diseases
A novel method for objective vision testing in canine models of inherited retinal disease.
Retinal Diseases
Analysis of six candidate genes as potential modifiers of disease expression in canine XLPRA1, a model for human X-linked retinitis pigmentosa 3.
Retinal Diseases
Development of a Pde6b Gene Knockout Rat Model for Studies of Degenerative Retinal Diseases.
Retinal Diseases
Exploring the Genetic Landscape of Retinal Diseases in North-Western Pakistan Reveals a High Degree of Autozygosity and a Prevalent Founder Mutation in ABCA4.
Retinal Diseases
Genetic mapping demonstrates that the alpha-subunit of retinal cGMP-phosphodiesterase is not the site of the rd mutation.
Retinal Diseases
Mechanisms of mutant PDE6 proteins underlying retinal diseases.
Retinal Diseases
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Retinal Dystrophies
A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium.
Retinal Dystrophies
Animal models of human retinal dystrophies.
Retinal Dystrophies
Identity-by-descent-guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy.
Retinal Dystrophies
Next-generation sequencing targeted disease panel in rod-cone retinal dystrophies in M?ori and Polynesian reveals novel changes and a common founder mutation.
Retinal Dystrophies
Reduced rhodopsin phosphorylation during retinal dystrophy.
Retinitis Pigmentosa
A homozygous PDE6B mutation in a family with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
A novel homozygous Ile535Asn mutation in the rod cGMP phosphodiesterase beta-subunit gene in two brothers of a Japanese family with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
A novel intronic mutation of PDE6B is a major cause of autosomal recessive retinitis pigmentosa among Caucasus Jews.
Retinitis Pigmentosa
AAV-mediated gene replacement either alone or in combination with physical and pharmacological agents results in partial and transient protection from photoreceptor degeneration associated with {beta}PDE deficiency.
Retinitis Pigmentosa
Apoptosis, retinitis pigmentosa, and degeneration.
Retinitis Pigmentosa
Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase.
Retinitis Pigmentosa
Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encoding the gamma subunit of rod cGMP phosphodiesterase.
Retinitis Pigmentosa
Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.
Retinitis Pigmentosa
Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line.
Retinitis Pigmentosa
Clinical characteristics and disease progression of retinitis pigmentosa associated with PDE6B mutations in Korean patients.
Retinitis Pigmentosa
Clinical Phenotype of PDE6B-Associated Retinitis Pigmentosa.
Retinitis Pigmentosa
Confirmation of tyrosine 698 in beta subunit of cGMP phosphodiesterase in patients with retinitis pigmentosa and population of the west of Mexico.
Retinitis Pigmentosa
Correction: Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients.
Retinitis Pigmentosa
Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects.
Retinitis Pigmentosa
Evidence for retinal remodelling in retinitis pigmentosa caused by PDE6B mutation.
Retinitis Pigmentosa
Exclusion of the PDE6A gene for generalised progressive retinal atrophy in 11 breeds of dog.
Retinitis Pigmentosa
Expanding the Clinical and Molecular Heterogeneity of Nonsyndromic Inherited Retinal Dystrophies.
Retinitis Pigmentosa
Expression and characterization of human PDEdelta and its Caenorhabditis elegans ortholog CEdelta.
Retinitis Pigmentosa
Frequency of mutations in the gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Genetic analysis of patients with retinitis pigmentosa using a cloned cDNA probe for the human gamma subunit of cyclic GMP phosphodiesterase.
Retinitis Pigmentosa
Genetic heterogeneity and consanguinity lead to a "double hit": homozygous mutations of MYO7A and PDE6B in a patient with retinitis pigmentosa.
Retinitis Pigmentosa
Genotype-phenotype correlation of mouse pde6b mutations.
Retinitis Pigmentosa
In vivo genome editing rescues photoreceptor degeneration via a Cas9/RecA-mediated homology-directed repair pathway.
Retinitis Pigmentosa
Lentivirus-mediated expression of cDNA and shRNA slows degeneration in retinitis pigmentosa.
Retinitis Pigmentosa
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa.
Retinitis Pigmentosa
Membrane protein transport in photoreceptors: the function of PDE?: the Proctor lecture.
Retinitis Pigmentosa
Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa.
Retinitis Pigmentosa
Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration.
Retinitis Pigmentosa
Novel immunodeficient Pde6b rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration.
Retinitis Pigmentosa
Novel mutations in PDE6B causing human retinitis pigmentosa.
Retinitis Pigmentosa
Novel PDE6B Mutation Presenting with Retinitis Pigmentosa - A Case Series of Three Patients.
Retinitis Pigmentosa
Photoreceptor cGMP phosphodiesterase delta subunit (PDEdelta) functions as a prenyl-binding protein.
Retinitis Pigmentosa
Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa.
Retinitis Pigmentosa
Reduced rod electroretinograms in carrier parents of two Japanese siblings with autosomal recessive retinitis pigmentosa associated with PDE6B gene mutations.
Retinitis Pigmentosa
Restoration of Vision in the pde6?-deficient Dog, a Large Animal Model of Rod-cone Dystrophy.
Retinitis Pigmentosa
Retinal remodeling.
Retinitis Pigmentosa
Screening of the PDE6B gene in patients with autosomal dominant retinitis pigmentosa.
Retinitis Pigmentosa
shRNA knockdown of guanylate cyclase 2e or cyclic nucleotide gated channel alpha 1 increases photoreceptor survival in a cGMP phosphodiesterase mouse model of retinitis pigmentosa.
Retinitis Pigmentosa
Structural disease progression in PDE6-associated autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
The delta subunit of rod specific cyclic GMP phosphodiesterase, PDE delta, interacts with the Arf-like protein Arl3 in a GTP specific manner.
Retinitis Pigmentosa
The gene therapy revolution in ophthalmology.
Retinitis Pigmentosa
The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase.
Retinitis Pigmentosa
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Therapeutic Margins in a Novel Preclinical Model of Retinitis Pigmentosa.
Retinitis Pigmentosa
Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6 (PDE6B) provide a model for human congenital stationary night blindness.
Retinitis Pigmentosa
Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.
Retinitis Pigmentosa
[A study of PDE6B gene mutation and phenotype in Chinese cases with retinitis pigmentosa]
Retinoblastoma
Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
Retinoblastoma
Expression of cone photoreceptor cGMP-phosphodiesterase alpha' subunit in Chinese hamster ovary, 293 human embryonic kidney, and Y79 retinoblastoma cells.
Retinoblastoma
Expression of the functional cone phototransduction cascade in retinoblastoma.
Retinoblastoma
Rod photoreceptor-specific gene expression in human retinoblastoma cells.
Retinoblastoma
The human cGMP-PDE beta-subunit promoter region directs expression of the gene to mouse photoreceptors.
Retinoschisis
Retinal imaging in inherited retinal diseases.
Rhabdomyolysis
Bilateral Knee and Intermittent Elbow Pain in a Competitive Archer/Hunter: Phosphodiesterase-5-Inhibitor-Statin Interaction?
Rhinitis
[Rhinitis medicamentosa].
Rosacea
Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases.
Schistosomiasis
Pulmonary vascular disease associated with schistosomiasis.
Scleroderma, Systemic
A clinical comparison of an endothelin receptor antagonist and phosphodiesterase-5 inhibitors for treating digital ulcers of systemic sclerosis.
Scleroderma, Systemic
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Scleroderma, Systemic
Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
Scleroderma, Systemic
Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels.
Scleroderma, Systemic
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Scleroderma, Systemic
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
Scleroderma, Systemic
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
Scleroderma, Systemic
The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species.
Scleroderma, Systemic
Vasoactive therapies in systemic sclerosis.
Scleroderma, Systemic
[Pulmonary arterial hypertension in connective tissue diseases]
Scleroderma, Systemic
[Pulmonary arterial hypertension related to connective tissue diseases]
Scotoma
PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH PHOSPHODIESTERASE-5 INHIBITOR THERAPY.
Seizures
Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model.
Seizures
Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.
Seizures
PDEI-5 for Erectile Dysfunction: A Potential Role in Seizure Susceptibility.
Seizures
Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.
Seizures
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Seizures
The interaction of sildenafil with the anticonvulsant effect of diazepam.
Seizures
[Epileptic seizures and vardenafil]
Sepsis
Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling.
Sexually Transmitted Diseases
Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
Sexually Transmitted Diseases
Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population.
Sexually Transmitted Diseases
Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors.
Shock, Cardiogenic
The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.
Sickle Cell Trait
Sickle cell trait and priapism: a case report and review of the literature.
Silicosis
Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis.
Skin Neoplasms
Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
Skin Neoplasms
Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.
Skin Neoplasms
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Skin Neoplasms
Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-?Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Skin Neoplasms
Systemic medications linked to an increased risk for skin malignancy.
Sleep Apnea, Obstructive
Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.
Sphincter of Oddi Dysfunction
Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction.
Spinal Cord Diseases
Urinary and sexual manifestations of patients infected by HTLV-I.
Spinal Cord Injuries
Current diagnosis and management of erectile dysfunction.
Spinal Cord Injuries
Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis.
Spinal Cord Injuries
Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury.
Spinal Cord Injuries
Management of erectile dysfunction.
Spinal Cord Injuries
Reply to 'Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis'.
Spinal Cord Injuries
Ten Years of Phosphodiesterase Type 5 Inhibitors in Spinal Cord Injured Patients.
Spinal Cord Injuries
The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury.
Spinal Cord Injuries
Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
Spinal Cord Injuries
[Subarachnoid hemorrhage due to autonomic dysreflexia : Rare consequence of sexual stimulation in a paraplegic.]
Spinal Dysraphism
Sexual dysfunction and infertility in the male spina bifida patient.
Spinal Stenosis
Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis.
Squamous Cell Carcinoma of Head and Neck
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Stomach Neoplasms
[Relationship between cyclic nucleotide phosphodiesterases (cPDE) and some patho-biologic behaviors of stomach cancer--I. Histochemical studies of CPDE in stomach cancer tissues]
Stroke
A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.
Stroke
Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Stroke
Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study.
Stroke
Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Stroke
Effects of the PDE5-inhibitor vardenafil in a mouse stroke model.
Stroke
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Stroke
Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.
Stroke
Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate.
Stroke
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Stroke
Novel phosphodiesterase-5 inhibitors: Current indications and future directions.
Stroke
PDE5 INHIBITOR TREATMENT OPTIONS FOR UROLOGIC AND NON- UROLOGIC INDICATIONS: 2012 UPDATE.
Stroke
PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Stroke
Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Stroke
Pituitary adenoma apoplexy associated with vardenafil intake.
Stroke
Role of sildenafil in neurological disorders.
Stroke
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis.
Stroke
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats.
Stroke
Sildenafil, a cyclic GMP phosphodiesterase inhibitor, induces microglial modulation after focal ischemia in the neonatal mouse brain.
Stroke
Tadalafil may improve cerebral perfusion in small-vessel occlusion stroke-a pilot study.
Stroke
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Stroke
Targeting nitric oxide in the subacute restorative treatment of ischemic stroke.
Stroke
Thymosin beta4: a candidate for treatment of stroke?
Stroke
Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke.
Stuttering
Daily tadalafil for the chronic phase of stuttering priapism: a case report.
Stuttering
How I manage priapism due to sickle cell disease.
Stuttering
Priapism and Sickle-Cell Anemia: Diagnosis and Nonsurgical Therapy.
Stuttering
Tissue expression, distribution, and regulation of PDE5.
Stuttering
Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.
Subarachnoid Hemorrhage
Acute Effect of Intravenous Sildenafil on Cerebral Blood Flow in Patients with Vasospasm After Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Acute Intracranial and Spinal Subdural Hematoma Associated with Vardenafil.
Subarachnoid Hemorrhage
Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats.
Subarachnoid Hemorrhage
Nonaneurysmal Subarachnoid Hemorrhage after Udenafil Intake.
Subarachnoid Hemorrhage
Phosphodiesterase 5 Inhibition Attenuates Cerebral Vasospasm and Improves Functional Recovery after Experimental Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Role of sildenafil in neurological disorders.
Syncope
Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Thromboangiitis Obliterans
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.
Thrombosis
Increased bleeding risk with phosphodiesterase-5 inhibitors after left ventricular assist device implantation.
Thrombosis
Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk.
Thrombosis
Reveals of candidate active ingredients in Justicia and its anti-thrombotic action of mechanism based on network pharmacology approach and experimental validation.
Thymoma
Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway.
Thyroid Neoplasms
Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Thyroid Neoplasms
PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.
Thyroiditis, Subacute
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Tuberculosis
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.
Tuberculosis
Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
Univentricular Heart
Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
Ureteral Calculi
Efficacy and safety of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi of 5 to 10 mm in size: A systematic review and network meta-analysis.
Ureteral Calculi
Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis.
Ureteral Obstruction
Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study.
Ureteral Obstruction
Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction.
Urethral Obstruction
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity.
Urethral Obstruction
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Urethral Obstruction
Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder.
Urethral Stricture
Effect of Tadalafil on Prevention of Urethral Stricture after Urethral Injury. an Experimental Study.
Urethral Stricture
Urethral diverticulum after endoscopic urethrotomy: case report.
Urinary Bladder Diseases
Hydrogen Sulfide and Urogenital Tract.
Urinary Bladder Neck Obstruction
Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder.
Urinary Bladder Neck Obstruction
Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats.
Urinary Bladder Neck Obstruction
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
Urinary Bladder Neck Obstruction
Effects of mirodenafil, a phosphodiesterase-5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model: physiological and immunohistochemical aspects.
Urinary Bladder Neck Obstruction
Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model.
Urinary Bladder Neck Obstruction
Long-term tadalafil administration can prevent functional and structural changes of the urinary bladder in male rats with partial bladder outlet obstruction.
Urinary Bladder Neck Obstruction
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Urinary Bladder Neoplasms
Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses.
Urinary Bladder, Neurogenic
Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors.
Urinary Bladder, Overactive
A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.
Urinary Bladder, Overactive
Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.
Urinary Bladder, Overactive
Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.
Urinary Bladder, Overactive
Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
Urinary Bladder, Overactive
Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
Urinary Bladder, Overactive
[Effects and mechanisms of phosphodiesterase type 5 inhibitors on rats with overactive bladder].
Urinary Bladder, Underactive
Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury.
Urinary Incontinence
[Urinary and sexual disorders following localised prostate cancer management].
Urination Disorders
[Combined treatment of patients with erectile dysfunction and urination disorders].
Urination Disorders
[Modern approaches to the treatment of patients with overactive bladder and urge urinary incontinence].
Urologic Diseases
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Usher Syndromes
Genetic analysis of patients with retinitis pigmentosa using a cloned cDNA probe for the human gamma subunit of cyclic GMP phosphodiesterase.
Usher Syndromes
The Time Course of Deafness and Retinal Degeneration in a Kunming Mouse Model for Usher Syndrome.
Uveitis
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.
Uveitis
Rapid affinity purification of retinal arrestin (48 kDa protein) via its light-dependent binding to phosphorylated rhodopsin.
Vascular Diseases
Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
Vascular Diseases
Intraurethral alprostadil for erectile dysfunction: a review of the literature.
Vascular Diseases
Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
Vascular Diseases
Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes.
Vascular Diseases
Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease.
Vascular Diseases
Tadalafil for the treatment of pulmonary arterial hypertension.
Vascular Diseases
Topical alprostadil cream for the treatment of erectile dysfunction.
Vascular Diseases
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Vasculitis
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasculitis, Central Nervous System
Treatment Algorithms in Systemic Lupus Erythematosus.
Vasospasm, Intracranial
Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats.
Vasospasm, Intracranial
Phosphodiesterase 5 Inhibition Attenuates Cerebral Vasospasm and Improves Functional Recovery after Experimental Subarachnoid Hemorrhage.
Venous Thrombosis
Treatment Algorithms in Systemic Lupus Erythematosus.
Ventricular Dysfunction, Left
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Ventricular Dysfunction, Left
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Ventricular Dysfunction, Left
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Ventricular Dysfunction, Left
Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.
Ventricular Dysfunction, Right
Evaluation of Clinical Outcomes with Phosphodiesterase-5 Inhibitor Therapy for Right Ventricular Dysfunction After Left Ventricular Assist Device Implantation.
Ventricular Dysfunction, Right
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction.
Vision Disorders
Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors.
Vision Disorders
Generation of an induced pluripotent stem cell line (FRIMOi007-A) derived from an incomplete achromatopsia patient carrying a novel homozygous mutation in PDE6C gene.
Vision Disorders
Literature commentary.
Vision Disorders
Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.
Vitelliform Macular Dystrophy
Retinal imaging in inherited retinal diseases.
Whooping Cough
Functional modifications of transducin induced by cholera or pertussis-toxin-catalyzed ADP-ribosylation.
Whooping Cough
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.
Whooping Cough
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Whooping Cough
Nucleotide exchange and cGMP phosphodiesterase activation by pertussis toxin inactivated transducin.
Whooping Cough
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Whooping Cough
Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP.
Whooping Cough
The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.